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other concurrent aberrant processes including neuroim-
mune activation, injury responses and/or general pertur-
bation of proteostasis. In human brain, αS deposition and 
neuronal degeneration are accentuated in distal axon/syn-
apse. Hyperbranching of axons is an anatomical common-
ality of Lewy-prone systems, providing a structural basis 
for abundance in distal axons and synaptic terminals. This 
neuroanatomical feature also can contribute to such dis-
tal accentuation of vulnerability in neuronal demise and 
the formation of αS inclusion pathology. Although retro-
grade progression of αS aggregation in hyperbranching 
axons may be a consistent feature of Lewy pathology, the 
regional distribution and gradient of Lewy pathology are 
not necessarily compatible with a predictable pattern such 
as upward progression from lower brainstem to cerebral 
cortex. Furthermore, “focal Lewy body disease” with 
the specific isolated involvement of autonomic, olfactory 
or cardiac systems suggests that spread of αS pathology 
is not always consistent. In many instances, the regional 
variability of Lewy pathology in human brain cannot be 
explained by a unified hypothesis such as transsynap-
tic spread. Thus, the distribution of Lewy pathology in 
human brain may be better explained by variable com-
binations of independent focal Lewy pathology to gen-
erate “multifocal Lewy body disease” that could be cou-
pled with selective but variable neuroanatomical spread 
of αS pathology. More flexible models are warranted to 
take into account the relative propensity to develop Lewy 
pathology in different Lewy-prone systems, even without 
interconnections, compatible with the expanding clin-
icopathological spectra of Lewy-related disorders. These 
revised models are useful to better understand the mecha-
nisms underlying the variable progression of Lewy body 
diseases so that diagnostic and therapeutic strategies are 
improved.
Abstract Progressive aggregation of alpha-synuclein 
(αS) through formation of amorphous pale bodies to 
mature Lewy bodies or in neuronal processes as Lewy 
neurites may be the consequence of conformational pro-
tein changes and accumulations, which structurally rep-
resents “molecular template”. Focal initiation and sub-
sequent spread along anatomically connected structures 
embody “structural template”. To investigate the hypoth-
esis that both processes might be closely associated and 
involved in the progression of αS pathology, which can 
be observed in human brains, αS amyloidogenic precur-
sors termed “seeds” were experimentally injected into the 
brain or peripheral nervous system of animals. Although 
these studies showed that αS amyloidogenic seeds can 
induce αS pathology, which can spread in the nervous sys-
tem, the findings are still not unequivocal in demonstrat-
ing predominant transsynaptic or intraneuronal spreads 
either in anterograde or retrograde directions. Interpre-
tation of some of these studies is further complicated by 
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Introduction
Eosinophilic inclusions with halo, now known as Lewy 
bodies, (LBs) were identified by Friedrich Heinrich Lewy 
in the dorsal motor nucleus of vagus (dmX) and substan-
tia innominata in the brains of patients with Parkinson dis-
ease (PD) [43, 69]. Initially, their presence in the substantia 
nigra (SN) was not readily recognized probably because 
they were less frequent in SN and their relevance to PD 
had not been established until Konstantin Nikolaevich Tre-
tiakoff identified a consistent association between nigral 
degeneration with LBs as a pathological substrate for PD 
[73, 114]. However, it remained unexplained how these 
inclusions at multiple brain regions were related to charac-
teristic motor deficits of PD until dopaminergic deficit of 
nigrostriatal system was identified as a major mechanism 
of PD [85, 164], largely involved in the motor presentation 
of PD. This nigra-centered explanation was reinforced after 
dramatic improvement by replacement therapy with levo-
dopa [6, 39].
Histochemical identification of Lewy pathology was 
improved by silver impregnations [175] and later by ubiq-
uitin or neurofilament immunohistochemistry (IHC) [71]. 
Ultimately, IHC for alpha-synuclein (αS), which is its 
major molecular component [168], is the most sensitive 
and specific gold standard to detect various types of Lewy 
pathologies. Amorphous early αS deposits in the neuronal 
cytoplasm, known as pale body and pale neurites [92], sug-
gests that initial amorphous αS deposits may evolve pro-
gressively into more aggregated typical LBs.
In addition to this progressive aggregation of αS in the 
neuronal cytoplasm and neurites, the identification of LBs in 
the cerebral cortices in patients with atypical dementia [102, 
103, 141] and in peripheral tissues [180] raised attention for 
their more extensive distribution that might explain other 
related clinical manifestations. Even after the identification 
of αS as a major component of LBs, however, it remains 
to be clarified how (when and where) LBs are formed [22, 
45]. Because Lewy pathology is more abundant in the lower 
brainstem in a majority of cases, it is generally assumed as 
if Lewy pathology is initiated in the lower brainstem and 
spreads into upper brainstem [21, 45]. This idea led to a 
hypothesis that conformational change of αS to form aggre-
gates might have templated itself to spread along neuroana-
tomical connections, which may be similar to prion disease, 
at least partly. Because this unified hypothesis is highly con-
venient and attractive to explain both local molecular change 
of αS as “a molecular template” and its stereotyped spread as 
“a structural template”, this combination is now enjoying the 
initial honeymoon of a happy marriage, when everything is 
usually considered in favor of this hypothesis. To make this 
marriage profoundly fruitful or at least acceptably fruitful 
even after the honeymoon period, some skepticism may be 
useful to recognize its potential pitfalls, possible misunder-
standings or misinterpretations, if any.
In this review, we will first discuss the molecular basis 
for some of the animal experimental studies that may sup-
port a conformational templating of αS protein, as a piv-
otal mechanism involved in neuroanatomical spread of αS 
pathology. However, we also consider how this simplistic 
mechanistic view does NOT fully take into account the 
global complexities of induced experimental paradigms 
and the variable presentations of human neuropathology. 
We explore the additional biological changes and unique 
neuroanatomical properties associated with Lewy pathol-
ogy that might provide alternative explanations for its dis-
tribution and clinical presentations. Indeed, specific neuro-
anatomical and morphological properties of select neuronal 
populations combined with alterations in multiple synergis-
tic pathogenic mechanisms likely explain the variable clini-
cal presentation of neurodegenerative diseases associated 
with Lewy pathology. αS pathology can often present with 
concomitant cerebral Amyloid β-protein (Aβ), tau and/or 
TAR DNA-binding protein-43 (TDP-43) inclusion pathol-
ogy which could influence both the formation of αS pathol-
ogy and the clinical findings in some patients [86, 104], but 
these topics are beyond the scope of this review.
Molecular template (experimental considerations)
Self‑templating of αS promoting in vitro amyloid 
aggregate formation
The in vitro polymerization of soluble monomeric αS into 
fibrils that are biochemically, morphologically and struc-
turally similar to those in human pathological inclusions 
is associated with a profound transformation in secondary 
structure from natively, unfolded random coil to predomi-
nantly β-pleated sheet [35, 36, 66, 79, 138, 166]. αS folded 
into β-pleated sheets is permissive to polymerizing into 
~10-nm-wide unbranched fibrils that have typical amyloi-
dogenic properties (Fig. 1) [36, 67, 68, 166, 186]. In vivo, 
αS is predominantly a neuronal soluble, unfolded protein 
[28, 60, 87], but a significant proportion is loosely associ-
ated with various cellular membranes driven by its ability 
to form amphipathic α-helical structures [42, 87, 98, 196]. 
Therefore, in its naïve state(s), αS is not primed to aggre-
gate into amyloid-type inclusions.
The in vitro polymerization of soluble αS into amy-
loid fibrils is characterized by a lag phase followed by a 
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rapid increase in fibril formation that can be promoted by 
increasing αS protein concentration [118, 138, 177, 191]. 
Therefore, it appears that the formation of a critical amount 
of αS amyloid precursors that may stochastically form in 
solution and is favored by increased protein concentration, 
which may also stabilize these structures due to increased 
protein interactions, is an important limiting step in driv-
ing αS amyloid formation. Experimentally, the simple 
addition of preformed fibrillar αS precursors (PFSPs), also 
termed “seeding” or “nucleation”, to overcome this thresh-
old can rapidly promote the recruitment of unstructured αS 
molecules into amyloidogenic permissive structure result-
ing into a synergistic formation of amyloid fibrils (Fig. 1) 
[191]. This in vitro process of using PFSPs to convert 
normal αS into amyloid precipitating the formation of 
mature pathological inclusions has been termed “conforma-
tional templating” and provides an interesting model that 
could explain, at least in part, the spread of αS pathology 
that tracks with progression of neurodegenerative process 
in human brains.
αS mutants accelerating or decelerating aggregation
Six missense mutations in the αS gene, SNCA, resulting 
in six different amino acid substitutions (A30P, E46K, 
H50Q, G51D, A53T, and A53E) have been identified that 
can cause PD with or without additional clinical features 
such as dementia reflecting a more widespread presentation 
Fig. 1  Schematic representation of the molecular changes result-
ing in αS pathological inclusions. a αS is naturally predominantly 
an unstructured, soluble protein (green shapes) that can randomly 
convert to acquire a β-pleated sheet conformation (red shapes). 
Once in this conformation αS can polymerize into longer amyloid 
precursor units and eventually fibrils (shown as negative stained αS 
fibrils assembled in vitro and observed by electron microscopy; bar 
100 nm) that coalesce to form pathological inclusions (shown as 
Lewy bodies: LBs, staining with an anti-αS antibody; bar 25 μm). b 
αS can potentially polymerize into amyloid precursor units and amy-
loidogenic fibrils that at the molecular level have subtle conforma-
tional differences (red shapes versus blue shapes) and these are not 
compatible for co-polymerizing resulting in a “strain”-like specific 
polymers
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of αS inclusion pathology typical of dementia with LBs 
(DLB) [5, 96, 107, 116, 145, 150, 151, 194]. In addition, 
short chromosomal duplications or trisomies containing 
the SCNA gene, plus relatively short flanking regions on 
chromosome 4, can also result in PD or DLB [31, 56, 167], 
indicating that a 50 % increase in the expression of αS is 
sufficient to cause these disorders. Genetic alternations 
resulting in increased αS expression are consistent with the 
notion described above that a higher abundance of αS can 
lead to a greater stochastic formation of αS PFSPs followed 
by conformational templating resulting in the spread of αS 
pathology. Alternatively, increased αS expression could 
also increase the focal formation of αS pathology with dis-
tribution perhaps reflecting selective vulnerability.
Consistent with conformational templating playing an 
important role in the spread of αS pathology, the A53T, 
H50Q and E46K αS mutations have consistently been 
shown to increase the rate of self-aggregation by these 
mutants [33, 35, 61, 67, 72, 95, 118, 138, 158]. While some 
reports suggest that A30P αS forms amyloid fibrils more 
slowly than wild-type (WT) αS [37], this finding has not 
been consistently observed by others [67, 138]. In addi-
tion, the A30P mutation appears to affect αS independently 
of protein aggregation, probably by partially impairing 
the ability of αS to bind to brain vesicles, likely due to a 
decreased likelihood to form α-helices [30, 52]. However, 
both the A53E and G51D αS mutations have been shown 
to significantly reduce the intrinsic propensity of αS to 
polymerize and aggregate, hence in principle, lowering 
amyloid transmissibility [55, 62, 157, 158], despite still 
causing early-onset PD with robust αS pathology [96, 116, 
145]. Collectively, there is no simple explanation for how 
all the known missense mutations in αS result in PD and 
their divergent effects on in vitro aggregate formation sug-
gest that conformational templating cannot solely account 
for disease progression.
Cellular models of αS release, uptake, transfer 
and inclusion formation
Many cell culture studies have demonstrated that several 
non-mutually exclusive mechanisms including release by 
exocytosis [109, 121], uptake by various endocytosis mech-
anisms [1, 110, 112, 171], release/uptake of exosomes [41, 
53], and release due to cell death could be involved in the 
intercellular transmission of αS aggregates. Using transfec-
tion reagents to drive membrane permeability, it was shown 
that the entry of a small amount of exogenous PFSPs into 
cells expressing αS is sufficient to efficiently induce endog-
enously expressed αS to form mature cytoplasmic amy-
loidogenic inclusions [126, 140, 188]. Thereafter, it was 
shown that the simple addition of extracellular PFSPs to 
primary neurons may be able to induce the formation of 
intracellular αS inclusions without the addition of other 
reagents [179], with the caveat that these studies were pre-
dominantly documented by immunostaining with antibody 
pSer129/81A (see below). Utilizing microfluidic devices to 
separate the soma and axonal projections from separate but 
adjacent and synapsed primary neuronal populations, it was 
shown that following neuronal uptake, PFSPs can move by 
both anterograde and retrograde axonal transport but that 
synaptic contact is not required for transfer between neu-
rons [58, 179].
Using recombinant adeno-associated viral (rAAV)-
mediated αS overexpression in mouse primary neuronal–
glial culture, it was demonstrated that exposure to exog-
enous PFSPs could efficiently induce intracellular αS 
inclusion pathology in cells overexpressing αS, and that 
this inclusion formation occurred in a fashion that was con-
sistent with conformational templating since the morphol-
ogy of the induced αS inclusions could be dictated by the 
type of PFSPs added [163]. Collectively, these cell culture 
studies have shown that under defined conditions confor-
mational templating of αS leading to inclusion formation 
can occur and they have provided insights into the cellu-
lar mechanisms that might be involved. However, it should 
also be considered that the concentrations of PFSPs used 
for most of these studies are beyond the physiological lev-
els of exogenous αS.
Anti‑phosphorylated Ser129 αS antibodies can label 
other phospho‑proteins and αS phosphorylation  
is induced by stress
Although phosphorylation of αS at Ser129 can be a robust 
marker of αS inclusion pathology (Suppl. Figure 1) as 
this residue is highly phosphorylated in human pathologi-
cal inclusions (~90 % phosphorylated in inclusions versus 
~4 % phosphorylated in total brain αS) [3, 24, 59, 187], 
phosphorylated Ser 129 (pSer129) immunoreactivity on 
histological sections should not be equated to the formation 
of αS inclusion without validation with other techniques. 
First, most pSer129 αS antibodies cross-react with other 
phosphorylated proteins. For example, αS pSer 129/81A 
antibody that has been used in many studies can strongly 
cross-react with phosphorylated low-molecule mass neuro-
filament subunits (NFL) and can give the false impression 
of αS inclusion pathology (Suppl. Figure 2) [162]. Not all 
αS pSer 129 antibodies that have been used in other studies 
also cross-react with phosphorylated NFL, but antibodies 
such as MJF-R13(8–8) can cross-react with other non-αS 
phosphorylated proteins (Suppl. Figures 1, 2). These facts 
highlight the need for well-characterized pSer129 αS anti-
bodies (e.g. as shown in Suppl. Figures 1, 2), especially for 
immunostaining studies. It is not surprising that antibod-
ies to phosphorylated αS Ser129 can cross-react with other 
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phospho-proteins since this epitope can be phosphorylated 
by multiple kinases, such as casein kinases and polo-like 
kinases [24], and thus this phospho-epitope has a high 
level of homology to many phosphorylation sites in other 
proteins that are also recognized and phosphorylated by 
these kinases. Second, many cellular stresses or insults can 
greatly increase the phosphorylation state of many proteins, 
including αS Ser129, without inducing inclusion formation 
[187]. Therefore, in human or experimental animal stud-
ies, increased staining for αS Ser129 should not be directly 
equated to inclusion formation without validation with 
other non-phospho-specific αS antibodies or other histo-
logical analyses.
Rodent studies of induction and spread of αS inclusion 
pathology
In the next sections, we discuss the studies utilizing αS 
transgenic mice and WT (i.e., non-transgenic) mice or rats 
that have been conducted to try to provide evidence that 
conformational templating of αS aggregates can occur 
in vivo, but we also critically highlight some of the techni-
cal shortcoming and the complexity in assessing the mech-
anisms involved in promoting αS inclusion pathology in 
these studies. In fact, some of the findings from these stud-
ies also support that other mechanisms can also be impor-
tant in driving the spread of αS pathology. Comparing the 
findings from these studies, utilizing αS transgenic and WT 
mice also provides important clues to biological barriers 
that are likely important to naturally suppress the spread of 
αS pathology. However, it is also important to note that the 
direct comparison of the findings from different groups can 
be complicated by differences in experimental conditions, 
for example the type of PFSPs used, which can be affected 
by many factors including the sonication conditions used 
for the preparations.
αS transgenic mouse models most commonly used 
for induction or transmission of αS pathology
Most of the αS transgenic mouse lines that were used to 
study transmission of αS pathological entities or αS con-
formational templating mechanisms were identically cre-
ated with the human αS cDNAs cloned into an expression 
vector where transgenic expression is driven by the mouse 
prion promoter [19]. Three of these transgenic mouse 
lines expressing WT human αS (line M20), A53T human 
αS (line M83) or E46K human αS (line M47) have been 
used. These αS transgenic mice predominantly express 
human αS throughout central nervous system (CNS) neu-
rons [54, 64] as would be expected from expression driven 
by mouse prion protein promoter [19]. The expression lev-
els in all three transgenic mouse lines are similar but the 
expression in M20 αS mice is modestly higher than for 
the M83 αS mice, while the expression in M47 αS mice 
is slightly lower [54, 64]. Importantly, as the mouse prion 
protein is not exclusively expressed in neurons, the expres-
sion driven by the mouse prion protein promoter occurs not 
only in CNS neurons, but also at substantial levels in glial 
cells especially in astrocytes [117, 181].
Native homozygous M83+/+ αS mice normally develop 
a late-onset (8–15 months of age) severe motor phenotype 
leading to death that results from the formation of neuronal 
αS amyloidogenic inclusions predominantly throughout 
the spinal cord, brain stem, thalamus and midbrain areas, 
and with some αS inclusions in the motor cortex [64]. 
Remarkably, dopaminergic nigral neurons are resilient to 
the formation of αS inclusions in these mice despite being 
surrounded by neurons with αS inclusions [64]. In addi-
tion, detailed analyses of the initial presentation of αS 
inclusions throughout the neuroaxis in these mice, before 
they are symptomatic, showed that they randomly appear 
without any clustering or direct evident of general spread 
[54]. This finding is more consistent with concurrent mul-
tifocal formation of αS inclusions with variable spreads as 
we suggest could explain some of the presentation of Lewy 
pathology in human brains (see below). Native hemizygous 
M83+/− αS mice can also develop similar pathologies and 
phenotype but these are delayed to later than 22 months of 
age. Native homozygous M20+/+ or hemizygous M20+/− 
αS mice do not develop any overt motor dysfunction or 
the presentation of αS pathology throughout their normal 
lifespan [54, 64]. Homozygous M47+/+ αS mice naturally 
develop a similar phenotype and neuroanatomical distribu-
tion of αS inclusions as the M83 αS mice but with a later 
onset (>15 months) and with morphologically distinct αS 
inclusions which are more round and compact reminiscent 
of human inclusions [54].
Brain extract injection in the cerebrum of αS transgenic 
mice to model pathogenic transmission
In studies aimed at demonstrating that αS pathology could 
be transmitted, young M83+/+ or M83+/− αS mice were 
injected in various brain regions with CNS extracts con-
taining αS aggregates from older motor impaired M83+/+ 
αS mice. These injections resulted in both an earlier pres-
entation of αS pathology and motor phenotype [13, 125, 
137, 184], and this induction was reportedly not observed 
in one set of M83+/+ αS mice injected with brain extracts 
generated from healthy M83 αS mice [137]. However, it 
is important to point out that these studies have not une-
quivocally demonstrated that αS itself was the inducer of 
pathology being transmitted as CNS extracts from diseased 
mice would contain potential inducers of many pathologi-
cal alterations including elevation in gliosis and various 
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cellular injury response activators. To definitely demon-
strate that the induction of pathology was specifically due 
to transmission of αS molecules, a key experimental con-
trol usually includes αS immuno-depletion where the αS 
present in the sample is removed by antibody absorption. 
Intracerebral injection of brain lysates from patients with 
multiple system atrophy (MSA) was also shown to induce 
αS inclusion pathology in M83+/− αS mice [184], but again 
αS immune depletion from these extracts was not per-
formed to demonstrate that the presence of αS aggregates 
was responsible for inducing these changes. In addition, the 
pattern of αS pathology induced in these studies was typi-
cal of the pattern observed in aging M83 αS mice such that 
the distribution did not appear to follow progression from 
the injection site [184] or that typically observed in MSA 
brain. Because clinicopathological differences between 
Lewy-related cytopathology and MSA are now well recog-
nized [132], it remains to be clarified whether the shared 
concept of “synucleinopathy” between MSA and PD/DLB 
is corroborated by such models. Similar experimental pas-
saging studies using CNS extracts from diseased mice into 
younger health αS transgenic mice to initiate earlier motor 
phenotype and αS pathology were also recently shown 
using αS transgenic mice with expression driven by the 
Thy-1 promoter [165]. Collectively, these studies showed 
that CNS extracts from αS mice or human brains that are 
undergoing neurodegeneration can induce pathology in αS 
overexpressing mice that are inherently primed as internal 
template but it still remains to be confirmed whether this 
was due to direct conformational templating by amyloido-
genic αS species and subsequent spatial spread. In addition, 
these studies heavily relied on pSer129 staining.
Soluble αS or PFSPs injection in the cerebrum of αS 
transgenic mice to model pathogenic transmission
A more direct experimental paradigm to try to demonstrate 
the involvement of αS conformational templating in the 
induction and spread of αS is the brain injection of in vitro 
produced recombinant PFSPs. The cerebral injection of 
recombinant, exogenous PFSPs can induce the formation 
of intracellular αS inclusion pathology in M83+/+ αS mice 
resulting in the typical motor impairments and paralysis 
characteristic of the phenotype that occurs in these mice 
with aging [13, 125, 162]. Furthermore, the observed 
induced αS pathology was consistent with progression from 
the brain injection sites used (e.g., hippocampal, cortical or 
striatal) with the induced brainstem and spinal cord pathol-
ogy likely reflecting the selective regional vulnerability of 
these transgenic mice [125, 162]. However, the majority 
of the white matter staining that was initially reported as 
an evidence for spread of αS pathology along white matter 
tracts [125] was later attributed to the cross-reactivity of the 
antibody anti-phosphorylated Ser129 (pSer129)/clone 81A 
with phosphorylated NFL [162].
In similar types of studies, intracerebral injections of 
PFSPs into adult M20+/− αS mice also resulted in a robust 
induction of αS inclusion pathology that spread over time 
from the site of injection [160]. However, cerebral injec-
tion of the non-amyloidogenic Δ71–82 αS deletion mutant, 
which under physiological conditions cannot form amyloid 
fibrils, directly influence the in vitro polymerization of nor-
mal αS or directly induce the seeding of αS inclusions in 
cultured cells [66, 126, 163, 189], was able to induce αS 
inclusion pathology, albeit less robustly than PFSPs [160]. 
In addition, the brain injection of PFSPs in adult M20+/− 
and M83+/+ αS mice resulted in the abnormal accumula-
tions of NFL and peripherin [160], a neuronal intermedi-
ate filament protein that can be expressed in the CNS as a 
result of injury response [9]. Furthermore, cerebral injec-
tion of PFSPs into M20+/− or M83+/+ αS mice induced the 
formation of additional protein inclusions immunoreactive 
for p62/sequestosome, a general marker of inclusion forma-
tion, that were not comprised of αS or NFL suggestive of a 
more general disruption of proteostasis [160]. Robust glio-
sis was induced from cerebral PFSP treatment and a sig-
nificant proportion of the induced αS inclusion pathology 
was observed in glial cells especially astrocytes [125, 160], 
which are rarely observed in human brain with PD. αS is 
normally a neuronal protein expressed only at low levels 
in glia [60, 63, 87–89, 134], so this robust αS pathology 
in glial cells likely reflects the ectopic, non-neuronal trans-
genic expression driven in these cells by the mouse prion 
protein promoter [117, 181]. Glial cells, similar to many 
other types of cells, can uptake and conceivably degrade 
exogenous PFSPs or amyloidogenic αS released by cells 
[108, 111, 154]. Therefore, glial cells can normally act as 
a barrier to the spread of αS pathology if indeed cellular 
release and reuptake are required (Fig. 2a). However, in αS 
transgenic mice created using the mouse prion protein pro-
moter, the ectopic expression of αS in glial cells, especially 
in astrocytes can result in a more widespread formation 
of αS inclusion pathology, thus exacerbating the spread 
of pathological inclusion and injury responses (Fig. 2b). 
In addition, this propagation of αS inclusion by glial cells 
does not have to follow neuroanatomical pathways.
For reasons that are still unclear, not every αS trans-
genic mouse lines demonstrate vulnerability leading to 
PFSP-induced αS pathology. In parallel stereotactic cer-
ebral injection studies of PFSPs in M47+/+ αS mice, these 
mice were relatively refractory to the spread of αS inclu-
sion pathology induced by PFSPs as αS inclusions were 
predominantly observed only at the site of injection [162]. 
Similar findings was obtained using PFSPs comprised of 
WT or E46K human αS demonstrating that this limited 
induction of αS was not due to incompatible heterotypic 
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interaction (i.e., cross-species differences) between PFSPs 
comprised of WT and E46K human αS.
Soluble αS or PFSPs injection in the brain of neonatal αS 
transgenic mice to model pathogenic transmission
Similar to the induction of αS inclusion pathology follow-
ing the injection of PFSPs in adult M20+/− αS mice, injec-
tion of PFSPs in M20+/− αS neonatal mice can induce 
the formation of αS inclusion pathology [159]. However, 
depending on the amount of PFSPs injected, the formation 
of αS inclusion pathology can appear only 8 months after 
the injection of PFSPs [159]. This finding is remarkable 
since the presence of the injected PFSPs in neonatal brains 
could only be detected for 2–4 days [159]. Similar to the 
studies using adult animals, induction of αS pathology was 
also observed following the brain injection of Δ71–82 αS 
in neonatal M20+/− αS mice, although again it was much 
less robust [159]. Overall, the induction of αS pathol-
ogy following the neonatal injection of exogenous αS in 
M20+/− αS mice was slower, less efficient and delayed 
compared to similar injections in adult mice which is likely 
due to the lower expression of murine and human trans-
genic αS in neonatal mouse brains [159], but these findings 
indicate that the initial brain injection of αS can trigger a 
slow biological cascade, perhaps partially involving the 
initial induction of abnormal αS aggregates and confor-
mational templating. These alterations can then result in 
the formation of mature αS inclusions long after the ini-
tial insult. Therefore, αS inclusion formation can be a very 
slow process that occurs below detectable levels until the 
aggregates coalesce to a visible size.
Peripheral (intramuscular) injection of soluble αS 
and PFSPs in αS transgenic mice
To further investigate the hypothesis that αS pathology 
can self-template and spread from the periphery into the 
CNS via peripheral nerves, PFSPs were injected in the 
hind leg muscle (either biceps femoris or gastrocnemius) 
in M83+/+, M83+/− or M20+/− αS mice [161]. In addition, 
an advantage of this simple non-CNS invasive procedure is 
that it does not alter brain homeostasis as does brain stereo-
tactic surgeries. The intramuscular (IM) injection of PFSPs 
in M83+/+ and M83+/− αS mice resulted in the rapid and 
synchronized development of hind limb motor weakness 
associated with robust induction of CNS αS pathology, 
predominantly in the spinal cord, brainstem and midbrain 
areas [161]. This pathological changes occurred at ~2 to 
3 months following IM injection in M83+/+ αS mice and 
Fig. 2  Diagrammatic representation of the mechanisms that can 
modulate the spread of αS inclusion pathology in WT and αS trans-
genic mice. a The cytoplasmic entry of PFSPs (red shapes) followed 
by the interaction with normally unstructured soluble αS molecules 
(green shapes) can induce their conversion into β-pleated sheet struc-
tures (1). In this form, αS can elongate into larger amyloidogenic pol-
ymers that coalesce into protein inclusions (2). Some of the amyloi-
dogenic αS species may be released by neurons into the extracellular 
space (3), but if uptake occurs by glial cells (e.g., astrocytes) (4) that 
do not express αS, this extracellular αS can be terminally degraded 
(5). b Similarly, in αS transgenic mice with expression driven by the 
mouse prion protein promoter, amyloidogenic αS species can also be 
released by neurons into the extracellular space and taken up by glial 
cells. However, due to the ectopic expression of αS in transgenic glial 
cells, this uptake can result in αS inclusion formation that enhances 
the spread of αS pathology
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~3 to 4 months for M83+/− αS mice. IM injections of 
PFSPs into M20+/− αS mice did not result in any motor 
phenotype, but induced a progressive accumulation of CNS 
αS inclusion pathology moving up the spinal cord detect-
able at 4 months post-injection and increasing thereafter up 
to 12 months, the last time point assessed [161]. To provide 
evidence that the induced CNS αS inclusion pathology fol-
lowing IM injection of PFSPs was due to retrograde trans-
port through the sciatic nerve (the major nerve that inner-
vates lower leg muscles), complete transection of the left 
sciatic nerve was performed 3 days prior to the IM injec-
tion of PFSPs in the left gastrocnemius muscle of M83+/− 
αS mice [161]. The sciatic nerve transection significantly 
delayed and in some mice perhaps completely prevented 
the induction of CNS αS inclusion pathology [161]. How-
ever, a subset of these mice still developed motor impair-
ment with CNS αS pathology identical to mice without 
nerve transection. These findings demonstrated that ret-
rograde transport of PFSPs is partially responsible for the 
induction of CNS αS pathology in this model, but either 
other routes including perhaps other minor nerves or trans-
port through blood may also be involved in inducing dis-
tant CNS αS pathology in predefined fashion. However, IM 
injection of soluble non-amyloidogenic Δ71–82 αS was 
also able to induce CNS αS inclusion pathology, albeit less 
efficiently than PFSPs, indicating that peripheral inocula-
tion of soluble αS must also be able to trigger the formation 
of CNS αS pathology by a mechanism that most likely does 
not involve protein conformational templating [161].
Evidence for αS pathogenic transmission and αS 
conformational templating in WT mice
Recasens and colleagues demonstrated that the nigral injec-
tion of LB-enriched extracts from the SN of postmortem 
PD brains can result in the progressive demise of nigros-
triatal dopaminergic neurons in mice associated with 
increased pSer129 staining and diffuse αS aggregates, 
but clearly defined LB-type inclusions were not observed 
[152]. In addition, increased levels of pSer129 staining 
were observed in distal but connected brain regions such 
as the striatum and motor cortex. The direct involvement of 
αS inducing these pathological changes was demonstrated 
in parallel studies with brain fractions lacking αS or injec-
tions in αS null mice. The neurotoxic effects of these LB-
containing extracts were additionally confirmed in nigral or 
striatal injection of monkey brain [152].
Cerebral injection of PFSPs can result in the formation 
of neuronal anti-pSer129 αS-reactive inclusions in WT 
mice [124, 130, 162, 173], but the extent that this apparent 
pSer129 αS pathology is due to aggregated, amyloidogenic 
αS has not been unequivocally established due to the over 
reliance on anti-pSer129 antibody staining. For example, 
the cerebral injection of exogenous αS can result in a rapid, 
robust but transient increase in pSer129/81A staining that is 
due to increased phosphorylated NFL staining [162]. Simi-
lar to the short half-life of PFSPs in neonatal brains, Mas-
uda-Suzukake and colleagues reported that injected PFSPs 
in adult brains demonstrated a half-life of less than 7 days 
[130], but about 30 days therefore pSer129-reactive inclu-
sions started to appear [130]. Cerebral injections of brain 
extracts from patients with αS inclusions were also able 
to induce pSer129-reactive inclusions in the brain of WT 
mice. Interestingly, the time lapse between the detection of 
the PFSPs and the appearance of detectable pSer129-reac-
tive inclusions suggests that some populations of PFSPs 
remain below detectable levels or that the PFSPs were able 
to initiate the seeding or slow formation of αS inclusions 
before being degraded.
Additional studies also suggest that brain αS inclusion 
pathology induced by the cerebral injections of PFSPs in 
WT mice appear to spread from the injection site [124, 129, 
173]. Again the majority of these data were mainly based 
on αS pSer129 immunostaining, but in some studies at 
least a subset of inclusions, but without a thorough parallel 
mapping of pathology distribution, were confirmed with an 
antibody to non-phosphorylated αS [124, 173]. This appar-
ent spread of αS inclusion pathology has been attributed 
to amyloid-like conformational templating. However, it is 
important to emphasize that a gradient of injected αS away 
from the injection site, possibly along normal anatomi-
cal connections, could lead to the progressive appearance 
of αS pathology. In this scenario, there could be progres-
sive “seeding” but no true spread except for distribution of 
the exogenous seeds. Consistent with this possibility, Rey 
and colleagues have shown that the injection of exogenous 
monomeric or aggregated αS in mouse olfactory bulb can 
result in the transport to neurons of neuroanatomically con-
nected brain regions, and here also the injected proteins 
had a short half-life (less than 72 h), but no induction of αS 
pathology was observed in these short-term studies [153]. 
Importantly, these experimental mouse studies also have 
not definitely addressed the direction (i.e., anterograde ver-
sus retrograde) of exogenous αS transport.
Not every PFSPs cerebral injection studies using mice 
expressing natural levels of αS have supported the notion 
that this challenge could lead to the induction and spread 
of authentic αS inclusion pathology. As such, the cerebral 
injection of PFSPs, which could robustly seed αS inclu-
sion pathology in cultured cells, only induced a very lim-
ited amount of αS inclusion pathology in mice that overex-
pressed tau protein but with normal levels of endogenous 
αS [75]. Moreover, in another study, the presence of αS 
inclusion pathology in WT mice following cerebral PFSP 
injection was limited to the injection site and it actually 
diminishes over time rather than progressively spreading 
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[162], suggestive of important biological barriers that can 
thwart the spread of αS inclusion pathology.
The peripheral IM injections of PFSPs in WT mice did 
not result in the induction of CNS αS pathology [161]. The 
lack of induction of CNS αS pathology following robust 
peripheral inoculation with PFSPs was also shown by Mas-
uda-Suzukake and colleagues where the intranasal adminis-
tration of 80 μg (4 × 20 μg) of PFSPs did not yield CNS 
pathology even almost 2 years after the exposure [130]. 
This paucity of CNS αS induction pathology in WT mice 
following the peripheral exposure to PFSPs is consistent 
with the normally low level of expression of endogenous 
αS in the peripheral nerve and the spinal cord in WT mice 
[63, 161]. This intrinsic low expression of αS in the PNS 
constitutes another nature barrier to transmission of αS 
inclusion pathology.
Rat studies of induction of αS pathology using exogenous 
αS
Paumier and colleges recently showed that the unilateral 
striatal injection of recombinant mouse PFSPs [146] in 
rats induces the formation pSer129/81A-reactive neu-
ronal aggregates that over time accumulate in areas that 
innervate the striatum such as the SN pars compacta, 
amygdala, frontal cortex and insular cortex. As noted 
above the pSer129/81A antibody can strongly cross-react 
with other phospho-proteins including NFL. The forma-
tion of protein inclusions was documented with other 
markers such as Nucleoporin 62/sequestosome-1 (p62/
SQSTM1), but localization with αS antibodies was weak 
[146]. Interestingly other brain regions, such as the locus 
coeruleus (LC) and the raphe, innervating to the stria-
tum did not develop pSer129/81A-positive accumula-
tions, suggesting selective neuronal vulnerability in this 
process. Despite the findings that pSer129/81A-positive 
accumulations were only observed in the ipsilateral SN 
pars compacta, similar bilateral demise of nigral dopa-
minergic neurons was observed [146] indicating that the 
injection of mouse PFSP must induce additional patho-
genic mechanisms in addition to protein conformational 
templating since αS inclusion formation was not required 
to induce the demise of these neurons and the induced 
toxic mechanism did not follow neuroanatomical path-
ways. Further supporting this notion is the findings that a 
similar unilateral striatal injection of soluble, non-aggre-
gated mouse αS can also induce similar pSer129/81A 
accumulations and the demise of nigral dopaminergic 
neurons, although the formation of protein aggregates 
occurred at a slower rate [146]. Interestingly, the number 
of pSer129/81A-reactive aggregates in the SN pars com-
pacta following the striatal injection of PFSPs decreased 
with time, despite nigral dopaminergic demise being 
similar, indicating that the formation of these aggregates 
can be reversible [146].
Peelaerts and colleagues recently showed that the direct 
rat nigral injections of PFSPs preparations with different 
structural properties defined as “fibrils” or “ribbons” were 
taken up by dopaminergic neurons and induced increased 
pSer129 immunoreactivity, but without a concomitant 
demise of nigral dopaminergic cells [147] demonstrating 
that these αS species were not intrinsically toxic. How-
ever, similar nigral injections of PFSPs in rats overex-
pressing human A53T αS in dopaminergic nigral neurons 
using rAAV (see below) could exacerbate the neurotoxic-
ity driven by A53T αS overexpression [147]. These stud-
ies also reported that some exogenous human PFSPs could 
be able to cross the blood–brain barrier and enter the CNS 
after tail vein injections, but this was accomplished using 
a substantial amount of PFSPs (80 μg total–8 injections of 
10 μg each) [147].
Pathological sequelae of local overexpression of αS 
through viral delivery
rAAV was used to mediate the expression of human αS 
in rat vagus nerve and specifically track the temporal and 
spatial distribution following αS expression [176]. As 
expected, human αS was initially detected in the medulla 
oblongata since the vagus nerve is comprised of axons that 
originate and terminate in the medulla oblongata and upper 
cervical spinal cord. However, at later time points human 
αS could also be detected in a limited number of more ros-
tral neuronal projections in the pons, midbrain, and fore-
brain. Interestingly, no exogenous human αS was found 
in cell bodies and it was not present in the SN pars com-
pacta. These findings were interpreted as an evidence for 
transneuronal caudal to rostral spread of αS.
Several studied have used viral vectors (rAAV or lenti-
virus) to express αS in adult rats’ or monkeys’ nigral dopa-
minergic neurons to assess the pathological consequences. 
Expression of human WT, A30P or A53T αS in rat or mon-
key nigral dopaminergic neurons using rAAV that stably 
expresses the transgene (>6 months) resulted in substan-
tial and specific demise of these neurons (30–80 % loss), 
concurrent with the formation of cellular αS cytoplas-
mic inclusions and dystrophic neurites [99–101]. Similar 
results were observed when using a lentiviral-based vec-
tor system to express αS proteins in rat nigral dopamin-
ergic neurons [122]. However, it is important to note that 
in these studies αS pathology was exclusively observed in 
the neuronal populations transduced to express human αS 
and that no evidence for transmission of αS pathology to 
other neuronal population was observed despite that they 
express endogenous αS. Nevertheless, since spread of αS 
pathology was not a major focus of these studies, such a 
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process could have been unnoticed. These findings further 
support the notion that there exist potent biological barri-
ers to prevent the inter-neuronal transmission of αS inclu-
sion pathology. It is also possible that the αS aggregates 
generated in these expression systems are not permissive 
to transmission.
Important issues and mechanisms to consider 
when interpreting experimental induction of αS 
inclusion pathology in rodents: potential pitfalls 
of experiments
Potential pitfalls of current experimental paradigms are 
summarized as follows:
Excessive amount of PFSPs
The amounts of PFSPs that were used experimentally to 
induce αS inclusion pathology in mice and rat are much 
larger that would normally be locally encountered even if 
many cells died simultaneously releasing αS aggregates. 
Thus, it is possible that in the experimental studies using 
PFSPs the natural barriers to induction and spread of αS 
induction pathology were artificially overwhelmed beyond 
concentrations that would normally occur. On the other 
hand, these studies are modeling human neurodegenerative 
diseases with changes progressively occurring throughout 
many years or decades and in aging brains that typically 
can have multiple proteinopathies likely reducing the nor-
mal abilities to cope with protein misfolding.
Questionable artificial enhancement of susceptibility
αS transgenic mice are much more susceptible to the induc-
tion and spread of αS protein inclusion pathology compared 
to WT mice [160–162]. Therefore, under normal expres-
sion levels induced αS inclusion pathology may not be 
very robust, suggesting that normal biological activities can 
cope with even a bolus insult of aggregated protein. The 
vulnerability of αS transgenic mice could be due to both 
the overexpression and ectopic, non-neuronal expression of 
transgenic αS. αS is naturally a highly expressed brain pro-
tein, so it is not surprising that transgenic overexpression 
renders these mice highly primed to the induction of pro-
tein aggregation.
Bystander contributions other than molecular 
conformations
Although studies using cerebral injection of PFSPs or brain 
extracts are suggestive of induction and spread of αS induc-
tion pathology by protein conformational templating, there 
are many important issues to consider that make it likely 
the experimental procedures potentiate this process and that 
several other mechanisms are involved (Fig. 3). The brain 
surgical stereotactic procedures used to inject exogenous 
αS cause both tissue and cellular damage that can greatly 
promote cellular uptake. Furthermore, it is difficult to com-
pletely rule out that some of the observed spread of αS 
pathology is not simply due to the dispersion of PFSPs in 
part due to the disruption of cerebral tissue due to needle 
injections. Once the formation of intracellular αS inclu-
sions have been initiated, these aggregates should actu-
ally serve as “magnets” to existing cellular amyloidogenic 
forms of αS thus hampering the spread of αS inclusion 
pathology at least until the cell demise, but in the experi-
mental cerebral injection models robust cell death associ-
ated with the spread of αS inclusion pathology has not been 
reported. In addition, the findings that challenges with solu-
ble αS including non-amyloidogenic Δ71–82 αS can also 
induce αS inclusion pathology in αS transgenic mice and 
WT rats [146, 159–161] strongly suggest that other mecha-
nisms are involved. If fact, it is possible that the cerebral 
injection of brain lysates or PFSPs have predominantly 
demonstrated the initiation of αS pathology due to biologi-
cal insults.
Proteostatic perturbations
The cerebral injection of PFSPs or brain lysates from ter-
minally motor impaired animals could lead to proteostatic 
perturbations, especially in primed αS transgenic mice 
thus initiating a progressive cycles of αS accumulation 
and aggregation. Mechanistically, the two major cyto-
plasmic protein degradation machineries, proteasome and 
lysosomal-autophagy, can be inhibited by various forms 
Fig. 3  Summary of biological 
mechanisms that may synergis-
tically promote neurodegenera-
tion with concomitant formation 
of αS inclusion formation
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of aggregated αS [38, 49, 50, 65, 127, 178, 192] that can 
contribute to the progressive spread of αS pathology. This 
notion would be consistent with a more global impairment 
in proteostasis that was noted in one study [160].
Glial involvement
The robust activation of gliosis that coincides with the for-
mation of αS inclusion pathology in the αS transgenic mod-
els challenged with PFSPs is also suggestive that this pro-
cess participates in the spread of pathology, either by the 
aberrant formation of αS in glial cells (Fig. 3) [125, 160] 
or by inducing inflammatory cellular damage [25, 70, 115]. 
The original injected PFSPs and additional soluble and 
aggregated αS released from damaged cells can be potent 
activators of inflammation [25, 34, 97, 115, 156, 195]. In 
addition, it should not be overlooked that various forms of 
exogenous αS could directly lead to cellular toxicity [40, 
51, 94, 120], which may also lead to spread of pathology 
by a positive-feedback process of cellular damage, inclu-
sion formation, and release of αS aggregates.
Structural template (neuroanatomical 
considerations)
Distally accentuated deficit of nigrostriatal and cardiac 
sympathetic systems: an intraneuronal gradient
In human brains, loss of nigral dopaminergic neurons with 
LB is the hallmark for PD [73] and explains the deficiency 
of dopamine in nigrostriatal system. The rate of LB forma-
tion is proportional to surviving nigral neurons and pre-
cedes their loss [74], although the real role of LB (toxic or 
protective) in PD remains to be clarified [113]. The number 
of surviving nigral neurons at the onset of motor deficits of 
PD is estimated to be 70 % of age-matched control [32]. 
This estimation is based on an extrapolation from different 
autopsy series. Deficiency of dopamine at their axon ter-
minals in caudate/putamen is more profound (30 % of age-
matched control) [32] than the loss of nigral neurons [85], 
indicating distally accentuated gradient of degeneration, 
also confirmed by PET studies in PD patients at the onset 
of motor deficits. It remains to be clarified what kind of 
structural changes are responsible for such distally accentu-
ated deficits in the human brains. However, tracing neur-
ite lesion in the human central nervous system is so com-
plex that the identity (dendrite or axons) and the polarity 
of neurites harboring pathological deposits are not always 
evident.
Examination of epicardial nerve fascicles provides a 
unique opportunity to evaluate how cardiac sympathetic 
nerves, frequently affected in PD in its early stage, are 
involved in PD. Histological comparison of cardiac sym-
pathetic nerve at different stages from presymptomatic 
PD (cases with LBs without clinical manifestations of PD, 
incidental LB disease: ILBD) to full-blown PD demon-
strated that αS deposition commences within distal axons 
at the presymptomatic phase and spreads towards the neu-
ronal perikarya followed by axonal demise [143] (Suppl. 
Figure 3). The simple morphology and connection of the 
cardiac sympathetic nerve clarified the anatomopathologi-
cal temporal substrate with distally accentuated αS depo-
sition followed by axonal depletion. Subsequent loss of 
noradrenalin terminals is detectable as decreased myocar-
dial uptake of radio-labeled meta-iodobenzylguanidine 
(MIBG) as a tracer relative to its mediastinal uptake as the 
reference (H/M ratio). One of the advantages of myocardial 
MIBG is its quantitative nature. Such a quantitative feature 
is hardly detected with other indices of autonomic func-
tions because autonomic functions are usually represented 
as a balance between sympathetic and parasympathetic sys-
tems. As a consequence, progressive decline of H/M ratio 
in PD patients may suggest a progressive depletion of sym-
pathetic axons in the cardiac tissue [142]. Indeed, direct 
comparison between remnant axons in epicardial nerve 
fascicles and myocardial uptake of MIBG (H/M ratio) per-
formed premortem in the same patients confirmed their 
quantitative correlation in a cohort with different stages 
from ILBD to dementia with LB (DLB) [172].
Distally accentuated vulnerability in hyper‑branched 
axons as a structural basis to template distal‑dominant 
neurodegeneration
It is proposed that LBs are preferentially formed in pro-
jection neurons with long, thin unmyelinated axons [20]. 
It is expected that energy/metabolic burdens and oxidative 
stress [80, 169] can be significantly accentuated in these 
types of neurons [149]. In addition, nigrostriatal axons 
are characterized by excessive branching, which expo-
nentially enhances these burdens by increasing the num-
ber of synapse at the each axon terminal (Fig. 4). Indeed, 
the number of striatal synapses from a single dopamin-
ergic neuron is estimated to be 102,165–245,103 in rat 
[131], while it is ten times more abundant to 1,000,000–
2,400,000 in human [18], which provides a basis for the 
distally accentuated vulnerability of nigrostriatal axons. 
Because some of the genes harboring mutation related to 
familial levodopa-responsive parkinsonism are related 
to mitochondria and their functions [128, 136], subse-
quent energy failure through mitochondrial dysfunc-
tion may predispose the nigrostriatal system to degen-
erate especially in axon terminals regardless of Lewy 
pathology [128]. Moreover, numerous axon terminals 
may serve as a portal of entry of external toxins such as 
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1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) or 
rotenone to template PD-like symptoms irrespective of 
Lewy pathology [14]. All of these are compatible with “a 
mitocentric view of PD” [76, 80].
Hyperbranching axons as a structural template 
for Lewy‑prone systems and their clinical 
manifestations
Lewy pathology is not restricted to the nigrostriatal system 
but also occurs in a variety of systems with different neu-
rotransmitters such as noradrenergic (sympathetic, LC), 
cholinergic (parasympathetic, nucleus basalis of Meynert), 
and serotoninergic (raphe nuclei, raphe) [20, 139] (Fig. 5). 
Although possible toxicity of dopamine and its metabolites 
may explain relative accentuation of nigral degeneration, 
the modality of neurotransmitter is not the major deter-
minant for LB formation. Instead, a unique structural 
characteristic common to these Lewy-prone systems is 
hyperbranching of long projection axons which innervate 
to wide areas in the brain as shown in Fig. 5 [170]. It is 
likely that this structural template similarly (1) increase 
the chance to develop αS deposition at these axon termi-
nals, which facilitates αS deposition and (2) this further 
exacerbates metabolic burden and oxidative stress at axon 
terminals in these Lewy-prone systems. Centripetal (retro-
grade) progression of axonal lesion as seen in nigrostriatal 
and cardiac sympathetic systems may be shared as a rule 
by these Lewy-prone systems with long projection axons. 
Of course, this does not necessarily exclude the possibil-
ity of intraneuronal spread in the reverse direction, from 








Fig. 4  Intraneuronal gradient/progression of Lewy pathology from 
axon terminals to neuronal soma. Nigrostriatal dopaminergic projec-
tions are characterized by long and thin axons with hyperbranching. 
This structural characteristic enhances distal vulnerability by increas-
ing the length of axons and the number of synaptic terminals, which 
exponentially enhance the energy burden especially at their distal 
ends. Normal axon terminals/distal axons (green) are gradually filled 
with αS (red) along disease progression as indicated by the horizon-
tal arrow to the right. Although it remains to be clarified how such 
energy expenditure is related to αS deposition, such hyperbranch-
ing state enhances the probability of distal axons and terminals to be 
involved and induces a vicious cycle through enhancing further the 
progressive compromise in the metabolic support by the decreased 
number of axons. αS deposition in swollen axons is one of the earliest 
axonal changes (pale neurite a). Because deposition of αS is frequent 
at branching points (Lewy neurites: LNs: b, c), hyperbranching axons 
as in the nigrostriatal system may facilitate αS deposition. They 
spread toward neuronal perikarya, where mature LBs (d) are formed. 
The outermost layer of LBs is composed of neurofilaments (green 
d), while the innermost layer is composed of ubiquitin (blue d) with 
αS in between (red d). This three-layered structure, confirmed also 
by immunoelectron microscopy (e) is shared between LNs (c) and 
LBs (d). Furthermore, each layer is continuous when a LN is in con-
tinuity with a LB (f), suggesting that LNs evolve into LBs or Lewy 
pathology spreads from axon to neuronal soma. (orange arrow); f, g 
modified from Kanazawa et al. [93]; e courtesy, Dr. Masakuni Arima 
(Director, Komoro Kogen Hospital)
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whether similar progression along axon is shared in olfac-
tory–amygdala axis [174] or in the striatum, where smaller 
neurons with shorter axons are intermingled.
From a clinical point of view, such a hyper-branched sta-
tus of long axon is correlated with their physiological func-
tions and their clinical manifestations without somatotopical 
presentation. For example, the dopamine deficiency of the 
nigrostriatal system is related to Parkinsonism and cognition. 
Cholinergic projections from nucleus basalis of Meynert 
are related to memory and cognition. Those from parasym-
pathetic nuclei (dorsal motor nucleus of vagus) are related 
to autonomic regulation. Serotonergic projections from 
raphe nuclei are related to anxiety, arousal, sleep or nocic-
eption. Noradrenergic projections from LC are related to 
mood, attention and gait. Thalamocortical projection may be 
related to fluctuation of dementia or hallucination [82]. Such 
“holistic organization based on large interconnectivity [46]” 
of Lewy-prone systems is in sharp contrast with the highly 
organized somatotopy in the primary motor efferent and the 
primary sensory afferent systems. Such organization is suit-
able to modulate final motor pathways or primary sensory 
pathways by exerting more generalized (non-localizationist) 
influence mainly in an indirect fashion. Consequently, clini-
cal manifestations related to these Lewy-prone systems are 
vague and generalized such that localizationist recognition of 
their clinical manifestations is practically difficult.
Axonal αS spreads toward LB in neuronal soma as in 
cardiac sympathetic nerve
Although it is established that αS-positive axons appear prior 
to the formation of LBs [23] (Suppl. Figure 3), it remains to 
be clarified how Lewy neurites (LNs, mainly in axon) and 
LBs are related. Three-dimensional analysis of triple-labeled 
LBs and LNs demonstrated a three-layered structure with 
neurofilament at the outermost layer, ubiquitin in the core 
and αS in between [93]. Because each of these three layers is 
continuous even at the branching point (Fig. 4c) and the junc-
tion between LB and LN (Fig. 4d), it is probable that some 
of LNs in axon may expand to form LB in soma, suggesting 
again that Lewy pathology extends from neurite to soma to 
form LB. Furthermore, LNs frequently occur at the branch-
ing point of axons (Fig. 4c), it is likely that some local envi-
ronment related to branching, such as trouble in transport, 
Fig. 5  Lewy-prone systems and 
neurotransmitters. Although the 
neurotransmitters are different 
between associated systems, 
these Lewy-prone systems are 
characterized by widespread 
innervation to cerebral cortex, 
basal ganglia, hippocampus 
through hyperbranching axons. 
Such structural template 
facilitates αS deposition. Such 
excessive branching of axons 
is also related to their normal 
functions or dysfunctions 
uniformly characterized by 
non-focal or generalized influ-
ences without somatotopy. nbM 
nucleus basalis of Meynert, 
dmX dorsal motor nucleus of 
vagus, SN substantia nigra, 
Raphe raphe nucleus, LC locus 
ceruleus, ggl. ganglia; modified 
from Nolte and Angevine [139] 
with permission
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may predispose αS deposition at each branching point [92]. 
Although the exact mechanisms for αS deposition at distal 
axon/synapse [10, 57] and for the preferential deposition at 
branching points still remain to be clarified, all of these find-
ings are compatible with the observation that spread of axonal 
αS deposition is followed by axonal depletion to yield the so-
called distal-dominant degeneration. Because hyperbranching 
of axons may predispose not only axon degeneration but is 
associated also with αS deposition, it is plausible that such 
structural characteristics may feature selective vulnerability 
of all Lewy-prone systems including peripheral sympathetic 
systems as their “structural template”. Distal axons could be 
dysfunctional or depleted early in the disease course even 
when their respective neuronal cell bodies remain relatively 
intact (intraneuronal gradient). Awareness of such early neur-
ite pathology before neuronal death [32, 119] will require the 
revision of the cell death-oriented paradigm of neurodegen-
eration to “neurite pathology” or “nexopathy”, so that earlier 
and more relevant to clinical manifestations are detected for 
early therapeutic intervention [27, 183].
Early autonomic involvement in PD
Autonomic nervous system outside the CNS serve as direct 
effectors (vasomotor, sudomotor, pilomotor, visceromotor) 
or includes primary sensory (viscerosensory) components. 
They are also characterized by unmyelinated hyperbranch-
ing axons and therefore frequently harbor αS deposits. 
Because cardiac sympathetic nerves could be affected even 
in asymptomatic patients with incidental LBs in the CNS 
[143] and there are some cases with αS deposits exclu-
sively in cardiac sympathetic axons without LB in the 
CNS [133], it is plausible that cardiac sympathetic nerves 
are one of the initial sites of Lewy pathology involvement. 
Some peripheral autonomic axons and ganglia are acces-
sible through skin [47] or gastrointestinal biopsies, which 
can be used to try to predict the presence of CNS LBs [83]. 
More extensive histological comparison of CNS, spinal and 
peripheral autonomic system for αS in an autopsy cohort 
of 98 patients without clinical manifestations of PD dem-
onstrated frequent involvement of spinal cord and periph-
eral autonomic nerves in parallel with olfactory bulb and 
dmX [15]. To address how these autonomic involvements 
by αS is related to PD, initially asymptomatic patients har-
boring chance identified αS deposits in surgical specimens 
of abdominopelvic organs were followed up for 30 months. 
Because UPDRD-II scores of these patients were higher 
and their myocardial uptake of MIBG (H/M ratio) was 
lower than in αS-negative controls, it is likely that such αS 
deposition in neurons of abdominopelvic organs represents 
one of the earliest stages of PD [135] or pure autonomic 
failure (PAF) [77]. Unexpected spreads of αS deposits 
including autonomic systems are not uncommon [7].
Possible discrepancies between αS deposition, 
neuroaxonal depletion and clinical manifestations
Since initial axonal accumulation of αS can be followed 
by loss of axons, the absence of αS deposits could repre-
sent either the absence of Lewy pathology or axonal deple-
tion after formation of Lewy pathology or by other causes 
such as ischemia. Thus, parallel evaluation of neuroaxonal 
components is necessary [4, 143]. Depletion of sympa-
thetic axons in the absence of αS deposits can suggest the 
presence of Lewy pathology elsewhere, unless otherwise 
explained by ischemia, for example. However, the absence 
of αS deposits may indicate either the total absence of 
Lewy pathology or loss of neuron after formation of Lewy 
pathology [74]. Therefore, αS IHC not assisted by evalu-
ation of neuroaxonal components could be misleading. 
Additional attention should be paid on possible influences 
of staining procedures and anti-αS antibodies, which may 
greatly alter αS immunoreactivity [2, 105, 148, 185]. Any-
way, abundant αS inclusion pathology in dmX may not 
necessarily be correlated with more profound neuronal 
depletion, while evident neuronal loss in the SN is not 
necessarily correlated with abundant αS deposits, which 
should be taken into account when considering regional 
gradient or lesion spread. Since distal axon and synapse are 
preferentially affected in LB disease before involvement 
of neuronal soma, it is possible that apparent preservation 
of neuronal soma does not assure the functional integrity. 
Therefore, discrepancies between αS deposition, neuroax-
onal depletion and clinical manifestations could be trivial 
and troublesome, which should be carefully correlated for 
sound interpretation. It remains to be clarified whether such 
discrepancies may be further enhanced or complemented 
by possible participation of αS oligomers, now selectively 
detectable with proximity ligation assay [155] or synaptic 
αS detectable with PET blot [106] in human brain. Finally, 
clinicopathological interpretations may be hampered by 
coexisting lesions other than αS [86, 104].
In summary, Lewy-prone systems are structurally char-
acterized by long hyperbranching axons that template dis-
tal-dominant degeneration with αS deposits. This degen-
erative process predominantly starts at distal axons and 
spreads in retrograde direction towards neuronal soma. 
This structural feature with barely somatotopic feature 
is also related to clinical presentations of PD/DLB. How 
these building blocks are organized into an order in this 
disorder is discussed below.
Possible mechanism for regional gradient 
(dmX > LC > SN) based on single hit hypothesis
As initially noted by Lewy, LBs in the dmX are usually 
more abundant than those in SN or LC in PD patients. 
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This regional gradient (dmX > LC > SN) was systemati-
cally demonstrated by Del Tredici and Braak [20, 45] based 
on a series of PD cases with LBs in dmX. Because their 
careful observations were based on serial thick sections to 
encompass the entire target nuclei, their irrefutable data are 
much more reliable and convincing than chance observa-
tion on routine single section used in other studies. Fur-
thermore, this apparent gradient in regional hierarchy is 
consistent with a hypothesis that αS deposition is always 
initiated at dmX and subsequently occurs in LC and finally 
in SN. Such translation of this stereotyped regional hierar-
chy into a predefined chronological unidirectional sequence 
provided a basis to construct a staging framework of PD 
based on αS deposition. As a more mechanistic interpre-
tation, this regional gradient is interpreted as a possible 
spread of αS deposition from the dmX to LC then SN along 
neural circuit, as if propagating transsynaptically. This spa-
tiotemporal axis proposed by this conceptualization greatly 
improved our understanding of PD by displaying its clin-
icopathological sequence on a defined timetable.
From single hit to multiple hit hypothesis
In addition to this putative upward progression of αS lesion 
from the lower brainstem to upper brainstem, independ-
ent involvement of olfactory–amygdala pathway by αS 
has been noted [81]. Although direct dopaminergic projec-
tion from SN to olfactory bulb was recently identified in 
rats [84], these two putative axes have been considered not 
contiguous inside the human brain. One of the alternative 
explanations for their co-occurrence is that some infec-
tious agents, like virus, may initiate olfactory involvements 
through nasal cavity and vagal involvements through ali-
mentary tract in parallel. This explanation with virus-like 
agent, however, awaits confirmation by identifying pos-
sible infectious agents. Nonetheless, the concept of this 
“dual-hit” hypothesis suggests a possibility that initiation 
of αS deposition is not necessarily monofocal and could 
be induced in multiple independent systems by some fac-
tors outside the neuraxis. How these Lewy-prone systems 
are related or not is one of the major issues in this series as 
discussed below.
Is the distribution of Lewy pathology sufficiently 
hierarchal to corroborate a unified hypothesis 
of unidirectional spread?
Typical gradient of Lewy pathology (dmX > LC > SN), 
initially proposed by Del Tredici and Braak [20, 45], is 
observed in some of (but not all) the cases in other series 
[78]. Data on this gradient in human brain are, however, 
still highly conflicting and cases with LB pathology not 
in agreement with this gradient are being accumulated [8, 
26, 90, 91, 144]. Moreover, exceptional cases with LBs in 
cerebral cortices with less involvement in the brainstem 
have been reported [103, 193], suggesting that initiation at 
the lower brainstem is not a prerequisite for development 
of LB pathology. Additional exceptions include (1) LBs 
only in cardiac sympathetic nerve [133], (2) their selective 
appearance only in LC [123], (3) their selective appear-
ance in the autonomic system as in PAF [77] and (4) REM 
sleep behavior disorder (RBD) which is frequently associ-
ated with Lewy pathology [17] and could be a prodrome 
long before the development of overt motor deficits of PD 
type. Although anatomopathological substrates for RBD 
remain to be clarified [16, 48], it is likely that Lewy pathol-
ogy different from typical PD which may be related to this 
peculiar clinical manifestations. Although such focal and 
isolated LB depositions are not in accordance with the typi-
cal gradient (dmX > LC > SN), these could be preludes to 
full-blown PD or DLB. Importantly, parkinsonism is not a 
necessary feature for these exceptional cases. These focal 
presentations of LBs could be termed “focal LB disease”, 
suggesting possible independent development of Lewy 
pathology in different Lewy-prone systems. Because such 
“non-motor” symptoms are clinically detectable even 
before the appearance of parkinsonism, how to take these 
“unpredictable” clinical features, possibly related to Lewy 
pathology, into account of diagnosis and management is 
one of the key issues in the clinical field. Nevertheless, the 
clinical and pathological heterogeneities indicate that the 
involvement of Lewy-prone systems is not exclusively ste-
reotyped as to corroborate its unidirectional spread.
Possible interneuronal connections 
between Lewy‑prone systems to explain disease 
evolution
Even though distribution of LB pathology could be het-
erogeneous, there are cases with typical gradient of Lewy 
pathology (dmX > LC > SN) as formulated by Braak and 
Del Tredici. Even though brainstem nuclei are intercon-
nected with each other directly or indirectly [44], it is not 
yet clarified which anatomical pathways may provide solid 
infrastructures to facilitate spreads of αS lesions across the 
systems from dmX, LC to SN in the human brainstem. It 
is worth considering how such gradient could be gener-
ated. As shown in Fig. 6, each of these systems is mainly 
equipped with major efferent projections with hyperbranch-
ing axons: upward projection from SN; downward projec-
tion from dmX; and both up- and downward projections 
from LC. In each system, αS lesion spreads retrogradely 
along these hyperbranching axons from axon terminal 
to neuron (Fig. 6, large orange arrows). If such intraneu-
ronal progression along these projecting axons is unidirec-
tional in each system (dmX, LC, SN), these intraneuronal 
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spreads are not sufficient to explain the upward progres-
sion from dmX, LC, to SN, which may require additional 
transsynaptic transmission. If axonal spread of αS deposit 
is retrograde and descending as shown in Fig. 6 (descend-
ing orange arrows to SN and LC), it is still necessary to 
explain the ascending αS pathology by other pathways. 
Additional projections form SN to LC (Fig. 6, gray inter-
rupted line) and that from LC to dmX (Fig. 6, gray inter-
rupted line) may be one of the candidate structures that 
may mediate transneuronal spread from dmX to LC (small 
arrow in orange) and that from LC to SN (arrowhead in 
orange). Even though such downward projections [182] 
from SN to LC [29] and those from LC to dmX [190] have 
been reported, it is not yet clarified whether these candi-
date or other connections are neuroanatomical substrates to 
facilitate predictable and stereotyped spreads of αS aggre-
gates between these LB-prone nuclei. Although complete 
neuroanatomical map for possible networks between these 
brainstem nuclei is far beyond the scope of this review, 
more detailed studies to demonstrate contiguous αS lesion, 
if any, by tracing along these candidate structures may 
reinforce the hypothesis of transneuronal spread by way of 
axon. Otherwise, morphological substrates for stereotyped 
progression of αS remain hypothetical in the human brain.
Could direction of intra‑ and interneuronal spread 
of αS be reversible?
Even if the connections discussed above would be avail-
able, this explanation may be faced with difficulties as 
shown below. Figure 7a, d shows the typical gradient of 
Lewy pathology (dmX > LC > SN). As fully discussed 
above, intraneuronal progression starts distally and spreads 
axonally towards neuronal soma (Fig. 6, orange arrows) 
in each system. If this regional gradient is mediated by 
transneuronal spread from dmX to LC (Fig. 7d, interrupted 
lines with arrow), aggregated αS in the dmX may be taken 
up by axon terminals and then spreads to the soma of LC 
neurons. Following transneuronal transfer of aggregated 
αS to LC neurons, it is expected to spread from soma of 
LC neurons to their distal axons, which is in the direc-
tion opposite to what would be occurring in Lewy-prone 
systems.
Figure 7b, e shows atypical gradient of Lewy pathol-
ogy (dmX < LC > SN). This time, LC neurons are ini-
tially involved from its distal axons as expected. When 
this αS pathology in LC neuron spreads to dmX (Fig. 7e), 
however, the direction of transneuronal spread is reversed 
(Fig. 7e, asterisk). It remains to be clarified whether the 
same axonal connection between dmX and LC could 
serve as bidirectional conduit or alternative connections 
are necessary to facilitate this reverse transmission. In 
either case, transport of αS aggregates to dmX soma may 
induce intraneuronal spread from soma to axon (Fig. 7e, 
orange arrow). If the regional gradient of αS lesions of 
human brain is explained by interneuronal transmis-
sion (Fig. 7d–f), the direction of intraneuronal and that 
of interneuronal transmission would have to be drasti-
cally reversed from a case to another. Although unified 
hypothesis of conformational template-like propagation 
may explain spread of αS lesion and its gradient, we have 
no unified mechanism to explain how neuroanatomical 
routes and direction of αS spread could be so variable at 
least in the human brain.
Fig. 6  Intraaxonal progression of Lewy pathology in Lewy-prone 
systems. αS pathology is initiated at distal axons and spreads toward 
neuronal cell bodies in each Lewy-prone system as indicated by 
orange arrow, respectively. This axonal spread is in parallel with the 
direction of the so-called the “upward spread” (broken and empty 
arrow containing “?”) up to LC. However, the direction of this axonal 
spread is “downward” above LC. Additional projections form SN 
to LC (gray interrupted line) and that from LC to dmX (gray inter-
rupted line) may be one of the candidate structures that may mediate 
transneuronal spread from dmX to LC (small arrow in orange) and 
that from LC to SN (arrowhead in orange), while these have not yet 
been documented in human brains with LB disease. DA dopamine, 
NA noradrenalin, IV forth ventricle, AC acetylcholine, SG sympa-
thetic ganglia, IML intermediolateral nucleus
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In contrast, Fig. 7a–c shows typical and atypical gradient 
of LB pathology. Intraneuronal spreads from axon to soma 
are shared among dmX, LC and SN regardless of the pri-
mary site of involvement. Note that this scheme is achieved 
only when interneuronal connections (interrupted lines in 
Fig. 7d–f) are eliminated. Because the underlying struc-
tures used as anatomopathological substrates for interneu-
ronal connections are not consistent, is it plausible to spec-
ulate that each Lewy-prone system could be more or less 
independent rather than being connected in a predefined 
order? This hypothesis based on “relative likelihood of dif-
ferent brain regions to manifest Lewy pathology [26]” may 
better explain why Lewy pathology may not necessarily be 
in conformity with the ascending spread in the brainstem or 
sometimes could even be isolated as “focal LB disease”. In 
other words, because the regional abundance of αS is not 
homogeneous in the human brain, the relative abundance 
of αS inclusion pathology (dmX > LC > SN) is not neces-
sarily consistent with a chronological scheme such as stag-
ing. Such awareness based on this more flexible hypothesis, 
in turn, may lead us to reconsider the framework of clini-
cal diagnosis of PD to enhance the clinical recognition of 
the wider spectrum of LB disease not restricted to PD or 
DLB [11, 12]. As described above, αS deposition in some 
parts of the human brain starts at axon terminals and subse-
quently spreads along projecting axons toward cell bodies. 
Unified spread of Lewy pathology from lower brainstem 
to upper brainstem may only be observed in some selected 
patients. However, the underlying neuroanatomical map to 
assure this unidirectional spread is not yet apparent. It is 
neither demonstrated whether the spread of αS lesion could 
be bidirectional (from axon to soma or from soma to axon) 
in human brain.
Alternatively, or more simply, Lewy pathology at least in 
the human brain could develop independently even without 
direct spread between contiguous structures. Such “system-
autonomous” development of Lewy pathology is related 
to the shared “structural template” of thin unmyelinated 
hyperbranching axon structures that facilitates LB pathol-
ogy (Figs. 4, 5), which provides the basis for the concept of 
“focal LB disease”. Because development of Lewy pathol-
ogy is facilitated more or less by such “structural tem-
plate”, gradients in lesion density could be determined by 
the relative propensity dependent on underlying structures 
Fig. 7  Non-connected or con-
nected explanations for variable 
gradient. Relative quantity of 
Lewy pathology could be quite 
variable with predominance at 
the dorsal motor nucleus (dmX, 
a, d), the locus coeruleus (LC, 
b, e) or the substantia nigra 
(SN, c, f). Putative directions 
of intraneuronal spread for 
αS inclusion pathology are 
indicated with orange or red 
arrows. Expected directions of 
possible transneuronal spread 
of αS inclusion pathology along 
interrupted lines are indicated 
with gray arrows and arrow-
heads. Either dmX (d), LC 
(e) or SN (f) is assumed to be 
initially involved and subse-
quently spread of αS inclusion 
pathology through interneuronal 
connections. Both intra- and 
inter-neuronal directions are 
reversed according to the pri-
mary site of involvement (d–f). 
See text for details
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(degree of divergence of axon, for example), influence of 
mitochondrial stress, or energy expenditure.
Of course, this system-autonomous explanation for LB 
pathology and its regional gradient does not exclude the 
possibility that transneuronal spreads of αS deposits and 
its uptake through neuronal soma are also taking part in 
human brain with PD. Currently, however, direct evidence 
to support this transneuronal spread and uptake is not yet 
clear in human brain with sporadic PD. Even without such 
transneuronal transmission, gradient of αS lesion and its 
variations could be well explained by independent devel-
opment of αS lesion in different systems not necessarily 
linked with each other.
Conclusions
Many studies and reviews on the topic of neurodegenera-
tive diseases with LBs are organized as if “molecular tem-
plate” for αS and its spread along “structural template” are 
unequivocally coupled to provide a direct mechanism to 
explain the progressive clinical and pathological nature of 
these disorders. This coupling of molecular and structural 
templates may be interesting, convenient and even relevant 
if both aspects share common molecular processes as at 
least partially demonstrated in several experimental studies. 
However, other aberrant mechanisms including neuroim-
mune activation, injury responses and/or general perturba-
tion of proteostasis, which can also result in promoting the 
spread of αS pathology, have also been implicated in these 
experiments. Furthermore, a direct association between 
molecular and structural templating as a general unified 
mechanism for spread of disease along neuropathological 
pathway would require a strictly directed inter-neuronal 
transmission (e.g., transsynaptic) of αS aggregates, but at 
this time the current experimental studies do not explic-
itly support this notion. Although this coupling may par-
tially explain stereotyped regional gradient of αS lesions 
in human brain, frequently accentuated in lower brainstem 
and its upward progression, this simplified hypothesis is 
not sufficient to account for the variable distribution of αS 
lesions in human brain ranging from focal LB disease to 
diffuse LB disease. Multifocal formation of Lewy pathol-
ogy with variable spreads may better explain the independ-
ent occurrence of Lewy pathology in different Lewy-prone 
systems as “multifocal LB disease”. In addition, axonal 
hyperbranching in combination with other intrinsic cellular 
properties affecting the abilities of various neurons to cope 
with misfolded, aggregated αS could result in neuronal 
populations with different and unique inherent propensi-
ties to internally template αS amyloid formation. These 
inherent differences in individual neuronal populations also 
could partially explain some of the disordered presentation 
of αS inclusion pathology in human brains. In contrast with 
the disordered regional distribution, intraneuronal distribu-
tion of Lewy-related degeneration is consistently accentu-
ated at distal axons and retrogradely spreads in an ordered 
fashion, which is predisposed by their hyperbranching as 
in the nigrostriatal axons. This order in retrograde spread 
along hyperbranching axons even in disordered regional 
distribution of αS of human brain is representative of Lewy 
pathology. Awareness of this human brain-oriented view is 
necessary and helpful not only in modeling the αS disor-
ders in animals but also in improving clinical practice for 
better diagnosis and therapy.
Acknowledgments This study was supported by Grants-in-Aid for 
Scientific Research (JSPS KAKENHI 25430057) from the Ministry 
of Education, Culture, Sports, Science and Technology; a Grant from 
the Japan Foundation for Neuroscience and Mental Health, the Mitsui 
Life Social Welfare Foundation, and the Tokyo Metropolitan Institute 
of Medical Science project “Mechanism for Early Diagnosis and Pre-
vention of Parkinson’s disease” to T.U. This work also was supported 
by Grants from the NINDS (NS089622) and the National Parkinson 
Foundation (NPF-UN203) to B.I.G. We are grateful to Ms Emiko 
Wakatsuki at Tokyo Metropolitan Institute of Medical Science for her 
excellent art work (Fig. 4).
Open Access This article is distributed under the terms of the 
Creative Commons Attribution 4.0 International License (http://crea-
tivecommons.org/licenses/by/4.0/), which permits unrestricted use, 
distribution, and reproduction in any medium, provided you give 
appropriate credit to the original author(s) and the source, provide a 
link to the Creative Commons license, and indicate if changes were 
made.
References
 1. Ahn KJ, Paik SR, Chung KC, Kim J (2006) Amino acid 
sequence motifs and mechanistic features of the membrane 
translocation of alpha-synuclein. J Neurochem 97(1):265–279
 2. Alafuzoff I, Parkkinen L, Al-Sarraj S, Arzberger T, Bell J, Bodi 
I, Bogdanovic N, Budka H, Ferrer I, Gelpi E, Gentleman S, 
Giaccone G, Kamphorst W, King A, Korkolopoulou P, Kovacs 
GG, Larionov S, Meyronet D, Monoranu C, Morris J, Parchi 
P, Patsouris E, Roggendorf W, Seilhean D, Streichenberger N, 
Thal DR, Kretzschmar H, BrainNet Europe C (2008) Assess-
ment of alpha-synuclein pathology: a study of the BrainNet 
Europe Consortium. J Neuropathol Exp Neurol 67(2):125–143. 
doi:10.1097/nen.0b013e3181633526
 3. Anderson JP, Walker DE, Goldstein JM, de Laat R, Banducci K, 
Caccavello RJ, Barbour R, Huang J, Kling K, Lee M, Diep L, 
Keim PS, Shen X, Chataway T, Schlossmacher MG, Seubert P, 
Schenk D, Sinha S, Gai WP, Chilcote TJ (2006) Phosphorylation 
of ser-129 is the dominant pathological modification of alpha-
synuclein in familial and sporadic Lewy body disease. J Biol 
Chem 281(40):29739–29752. doi:10.1074/jbc.M600933200
 4. Annerino DM, Arshad S, Taylor GM, Adler CH, Beach TG, 
Greene JG (2012) Parkinson’s disease is not associated with 
gastrointestinal myenteric ganglion neuron loss. Acta Neuro-
pathol 124(5):665–680. doi:10.1007/s00401-012-1040-2
 5. Appel-Cresswell S, Vilarino-Guell C, Encarnacion M, Sher-
man H, Yu I, Shah B, Weir D, Thompson C, Szu-Tu C, Trinh 
J, Aasly JO, Rajput A, Rajput AH, Jon SA, Farrer MJ (2013) 
67Acta Neuropathol (2016) 131:49–73 
1 3
Alpha-synuclein p. H50Q, a novel pathogenic mutation for 
Parkinson’s disease. Mov Disord 28(6):811–813. doi:10.1002/
mds.25421
 6. Barbeau A (1969) L-dopa therapy in Parkinson’s disease: a 
critical review of nine years’ experience. Can Med Assoc J 
101(13):59–68
 7. Beach TG, Adler CH, Sue LI, Vedders L, Lue L, White Iii CL, 
Akiyama H, Caviness JN, Shill HA, Sabbagh MN, Walker DG, 
Arizona Parkinson’s Disease C (2010) Multi-organ distribution 
of phosphorylated alpha-synuclein histopathology in subjects 
with Lewy body disorders. Acta Neuropathol 119(6):689–702. 
doi:10.1007/s00401-010-0664-3
 8. Beach TG, White CL, Hamilton RL, Duda JE, Iwatsubo T, Dick-
son DW, Leverenz JB, Roncaroli F, Buttini M, Hladik CL, Sue 
LI, Noorigian JV, Adler CH (2008) Evaluation of alpha-synuclein 
immunohistochemical methods used by invited experts. Acta 
Neuropathol 116(3):277–288. doi:10.1007/s00401-008-0409-8
 9. Beaulieu JM, Kriz J, Julien JP (2002) Induction of peripherin 
expression in subsets of brain neurons after lesion injury or cer-
ebral ischemia. Brain Res 946(2):153–161
 10. Bellucci A, Navarria L, Zaltieri M, Missale C, Spano P (2012) 
Alpha-synuclein synaptic pathology and its implications in 
the development of novel therapeutic approaches to cure Par-
kinson’s disease. Brain Res 1432:95–113. doi:10.1016/j.
brainres.2011.11.031
 11. Berg D, Lang AE, Postuma RB, Maetzler W, Deuschl G, Gas-
ser T, Siderowf A, Schapira AH, Oertel W, Obeso JA, Olanow 
CW, Poewe W, Stern M (2013) Changing the research cri-
teria for the diagnosis of Parkinson’s disease: obstacles and 
opportunities. Lancet Neurol 12(5):514–524. doi:10.1016/
S1474-4422(13)70047-4
 12. Berg D, Postuma RB, Bloem B, Chan P, Dubois B, Gasser T, 
Goetz CG, Halliday GM, Hardy J, Lang AE, Litvan I, Marek K, 
Obeso J, Oertel W, Olanow CW, Poewe W, Stern M, Deuschl 
G (2014) Time to redefine PD? Introductory statement of the 
MDS task force on the definition of Parkinson’s disease. Mov 
Disord 29(4):454–462. doi:10.1002/mds.25844
 13. Betemps D, Verchere J, Brot S, Morignat E, Bousset L, Gail-
lard D, Lakhdar L, Melki R, Baron T (2014) Alpha-synuclein 
spreading in M83 mice brain revealed by detection of patholog-
ical alpha-synuclein by enhanced elisa. Acta Neuropathol Com-
mun 2:29. doi:10.1186/2051-5960-2-29
 14. Blesa J, Pifl C, Sanchez-Gonzalez MA, Juri C, Garcia-Cabezas 
MA, Adanez R, Iglesias E, Collantes M, Penuelas I, Sanchez-
Hernandez JJ, Rodriguez-Oroz MC, Avendano C, Hornykiewicz 
O, Cavada C, Obeso JA (2012) The nigrostriatal system in the 
presymptomatic and symptomatic stages in the MPTP monkey 
model: a PET, histological and biochemical study. Neurobiol 
Dis 48(1):79–91. doi:10.1016/j.nbd.2012.05.018
 15. Bloch A, Probst A, Bissig H, Adams H, Tolnay M (2006) 
Alpha-synuclein pathology of the spinal and peripheral auto-
nomic nervous system in neurologically unimpaired elderly 
subjects. Neuropathol Appl Neurobiol 32(3):284–295. 
doi:10.1111/j.1365-2990.2006.00727.x
 16. Boeve BF, Silber MH, Ferman TJ, Lin SC, Benarroch EE, 
Schmeichel AM, Ahlskog JE, Caselli RJ, Jacobson S, Sabbagh 
M, Adler C, Woodruff B, Beach TG, Iranzo A, Gelpi E, San-
tamaria J, Tolosa E, Singer C, Mash DC, Luca C, Arnulf I, Duy-
ckaerts C, Schenck CH, Mahowald MW, Dauvilliers Y, Graff-
Radford NR, Wszolek ZK, Parisi JE, Dugger B, Murray ME, 
Dickson DW (2013) Clinicopathologic correlations in 172 cases 
of rapid eye movement sleep behavior disorder with or without 
a coexisting neurologic disorder. Sleep Med 14(8):754–762. 
doi:10.1016/j.sleep.2012.10.015
 17. Boeve BF, Silber MH, Saper CB, Ferman TJ, Dickson DW, 
Parisi JE, Benarroch EE, Ahlskog JE, Smith GE, Caselli RC, 
Tippman-Peikert M, Olson EJ, Lin SC, Young T, Wszolek 
Z, Schenck CH, Mahowald MW, Castillo PR, Del Tredici K, 
Braak H (2007) Pathophysiology of REM sleep behaviour dis-
order and relevance to neurodegenerative disease. Brain 130(Pt 
11):2770–2788. doi:10.1093/brain/awm056
 18. Bolam JP, Pissadaki EK (2012) Living on the edge with too 
many mouths to feed: why dopamine neurons die. Mov Disord 
27(12):1478–1483. doi:10.1002/mds.25135
 19. Borchelt DR, Davis J, Fischer M, Lee MK, Slunt HH, Ratovit-
sky T, Regard J, Copeland NG, Jenkins NA, Sisodia SS, Price 
DL (1996) A vector for expressing foreign genes in the brains 
and hearts of transgenic mice. Genet Anal 13(6):159–163
 20. Braak E, Del Tredici K (2009) Neuroanatomy and pathology of 
sporadic Parkinson’s disease, vol 201., Advances in anatomy, 
embryology and cell biologySpringer, Berlin
 21. Braak H, Bohl JR, Müller CM, Rüb U, de Vos RA, Del Tredici 
K (2006) Stanley Fahn lecture 2005: the staging procedure for 
the inclusion body pathology associated with sporadic Parkin-
son’s disease reconsidered. Mov Disord 21(12):2042–2051. 
doi:10.1002/mds.21065
 22. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, 
Braak E (2003) Staging of brain pathology related to sporadic 
Parkinson’s disease. Neurobiol Aging 24(2):197–211
 23. Braak H, Sastre M, Bohl JR, de Vos RA, Del Tredici K (2007) 
Parkinson’s disease: lesions in dorsal horn layer I, involve-
ment of parasympathetic and sympathetic pre- and postgangli-
onic neurons. Acta Neuropathol 113(4):421–429. doi:10.1007/
s00401-007-0193-x
 24. Braithwaite SP, Stock JB, Mouradian MM (2012) Alpha-
synuclein phosphorylation as a therapeutic target in Parkin-
son’s disease. Rev Neurosci 23(2):191–198. doi:10.1515/
revneuro-2011-0067
 25. Brundin P, Li JY, Holton JL, Lindvall O, Revesz T (2008) 
Research in motion: the enigma of Parkinson’s disease pathol-
ogy spread. Nat Rev Neurosci 9(10):741–745. doi:10.1038/
nrn2477
 26. Burke RE, Dauer WT, Vonsattel JP (2008) A critical evaluation 
of the Braak staging scheme for Parkinson’s disease. Ann Neu-
rol 64(5):485–491. doi:10.1002/ana.21541
 27. Burke RE, O’Malley K (2013) Axon degeneration in Par-
kinson’s disease. Exp Neurol 246:72–83. doi:10.1016/j.
expneurol.2012.01.011
 28. Burre J, Vivona S, Diao J, Sharma M, Brunger AT, Sudhof 
TC (2013) Properties of native brain alpha-synuclein. Nature 
498(7453):E4–E6. doi:10.1038/nature12125
 29. Cedarbaum JM, Aghajanian GK (1978) Afferent projections 
to the rat locus coeruleus as determined by a retrograde trac-
ing technique. J Comp Neurol 178(1):1–16. doi:10.1002/
cne.901780102
 30. Chandra S, Gallardo G, Fernández-Chacón R, Schlüter OM, 
Südhof TC (2005) Alpha-synuclein cooperates with CSPalpha 
in preventing neurodegeneration. Cell 123(3):359–361
 31. Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, 
Douay X, Lincoln S, Levecque C, Larvor L, Andrieux J, Huli-
han M, Waucquier N, Defebvre L, Amouyel P, Farrer M, Destee 
A (2004) Alpha-synuclein locus duplication as a cause of famil-
ial Parkinson’s disease. Lancet 364(9440):1167–1169
 32. Cheng HC, Ulane CM, Burke RE (2010) Clinical progression in 
Parkinson disease and the neurobiology of axons. Ann Neurol 
67(6):715–725. doi:10.1002/ana.21995
 33. Choi W, Zibaee S, Jakes R, Serpell LC, Davletov B, Crowther 
RA, Goedert M (2004) Mutation E46K increases phospholipid 
binding and assembly into filaments of human alpha-synuclein. 
FEBS Lett 576(3):363–368
 34. Codolo G, Plotegher N, Pozzobon T, Brucale M, Tessari I, 
Bubacco L, de Bernard M (2013) Triggering of inflammasome 
68 Acta Neuropathol (2016) 131:49–73
1 3
by aggregated alpha-synuclein, an inflammatory response in 
synucleinopathies. PLoS One 8(1):e55375. doi:10.1371/journal.
pone.0055375
 35. Conway KA, Harper JD, Lansbury PT (1998) Accelerated 
in vitro fibril formation by a mutant alpha-synuclein linked to 
early-onset Parkinson disease. Nat Med 4(11):1318–1320
 36. Conway KA, Harper JD, Lansbury PT (2000) Fibrils formed 
in vitro from alpha-synuclein and two mutant forms linked 
to Parkinson’s disease are typical amyloid. Biochemistry 
39(10):2552–2563
 37. Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, 
Lansbury PT (2000) Acceleration of oligomerization, not 
fibrillization, is a shared property of both alpha-synuclein 
mutations linked to early-onset Parkinson’s disease: implica-
tions for pathogenesis and therapy. Proc Natl Acad Sci USA 
97(2):571–576
 38. Cookson MR (2005) The biochemistry of Parkinson’s disease. 
Annu Rev Biochem 74:29–52
 39. Cotzias GC, Papavasiliou PS, Gellene R (1969) Modification 
of Parkinsonism—chronic treatment with l-dopa. N Engl J Med 
280(7):337–345. doi:10.1056/NEJM196902132800701
 40. Cremades N, Cohen SI, Deas E, Abramov AY, Chen AY, 
Orte A, Sandal M, Clarke RW, Dunne P, Aprile FA, Berton-
cini CW, Wood NW, Knowles TP, Dobson CM, Klenerman 
D (2012) Direct observation of the interconversion of normal 
and toxic forms of alpha-synuclein. Cell 149(5):1048–1059. 
doi:10.1016/j.cell.2012.03.037
 41. Danzer KM, Kranich LR, Ruf WP, Cagsal-Getkin O, Winslow 
AR, Zhu L, Vanderburg CR, McLean PJ (2012) Exosomal cell-
to-cell transmission of alpha synuclein oligomers. Mol Neuro-
degener 7:42. doi:10.1186/1750-1326-7-42
 42. Davidson WS, Jonas A, Clayton DF, George JM (1998) Stabi-
lization of alpha-synuclein secondary structure upon binding to 
synthetic membranes. J Biol Chem 273(16):9443–9449
 43. Del Tredici K, Braak H (2012) Lewy pathology and neuro-
degeneration in premotor Parkinson’s disease. Mov Disord 
27(5):597–607. doi:10.1002/mds.24921
 44. Del Tredici K, Braak H (2013) Dysfunction of the locus coer-
uleus-norepinephrine system and related circuitry in Parkin-
son’s disease-related dementia. J Neurol Neurosurg Psychiatry 
84(7):774–783. doi:10.1136/jnnp-2011-301817
 45. Del Tredici K, Rüb U, De Vos RA, Bohl JR, Braak H (2002) 
Where does Parkinson disease pathology begin in the brain? J 
Neuropathol Exp Neurol 61(5):413–426
 46. Diederich NJ, Parent A (2012) Parkinson’s disease: acquired 
frailty of archaic neural networks? J Neurol Sci 314(1–2):143–
151. doi:10.1016/j.jns.2011.10.003
 47. Doppler K, Ebert S, Uceyler N, Trenkwalder C, Ebentheuer J, 
Volkmann J, Sommer C (2014) Cutaneous neuropathy in Par-
kinson’s disease: a window into brain pathology. Acta Neuro-
pathol 128(1):99–109. doi:10.1007/s00401-014-1284-0
 48. Dugger BN, Boeve BF, Murray ME, Parisi JE, Fujishiro H, 
Dickson DW, Ferman TJ (2012) Rapid eye movement sleep 
behavior disorder and subtypes in autopsy-confirmed demen-
tia with Lewy bodies. Mov Disord 27(1):72–78. doi:10.1002/
mds.24003
 49. Ebrahimi-Fakhari D, McLean PJ, Unni VK (2012) Alpha-
synuclein’s degradation in vivo: opening a new (cranial) win-
dow on the roles of degradation pathways in Parkinson disease. 
Autophagy 8(2):281–283. doi:10.4161/auto.8.2.18938
 50. Ebrahimi-Fakhari D, Saidi LJ, Wahlster L (2013) Molecular 
chaperones and protein folding as therapeutic targets in Parkin-
son’s disease and other synucleinopathies. Acta Neuropathol 
Commun 1(1):79. doi:10.1186/2051-5960-1-79
 51. El Agnaf OM, Jakes R, Curran MD, Middleton D, Ingenito R, 
Bianchi E, Pessi A, Neill D, Wallace A (1998) Aggregates from 
mutant and wild-type alpha-synuclein proteins and NAC pep-
tide induce apoptotic cell death in human neuroblastoma cells 
by formation of beta-sheet and amyloid-like filaments. FEBS 
Lett 440(1–2):71–75
 52. Eliezer D, Kutluay E, Bussell R Jr, Browne G (2001) Confor-
mational properties of alpha-synuclein in its free and lipid-asso-
ciated states. J Mol Biol 307(4):1061–1073
 53. Emmanouilidou E, Melachroinou K, Roumeliotis T, Garbis SD, 
Ntzouni M, Margaritis LH, Stefanis L, Vekrellis K (2010) Cell-
produced alpha-synuclein is secreted in a calcium-dependent 
manner by exosomes and impacts neuronal survival. J Neurosci 
30(20):6838–6851
 54. Emmer KL, Waxman EA, Covy JP, Giasson BI (2011) E46K 
human alpha-synuclein transgenic mice develop Lewy-like and 
tau pathology associated with age-dependent, detrimental motor 
impairment. J Biol Chem 286(40):35104–35118
 55. Fares MB, Ait-Bouziad N, Dikiy I, Mbefo MK, Jovicic A, Kiely 
A, Holton JL, Lee SJ, Gitler AD, Eliezer D, Lashuel HA (2014) 
The novel Parkinson’s disease linked mutation G51D attenuates 
in vitro aggregation and membrane binding of alpha-synuclein, 
and enhances its secretion and nuclear localization in cells. 
Hum Mol Genet 23(17):4491–4509. doi:10.1093/hmg/ddu165
 56. Farrer M, Kachergus J, Forno L, Lincoln S, Wang DS, Hulihan 
M, Maraganore D, Gwinn-Hardy K, Wszolek Z, Dickson D, 
Langston JW (2004) Comparison of kindreds with Parkinson-
ism and alpha-synuclein genomic multiplications. Ann Neurol 
55(2):174–179
 57. Fortin DL, Nemani VM, Edwards RH (2008) A-synuclein, 
CSPa, SNAREs and neuroprotection in vivo. In: Naas R, 
Przedborski S (eds) Parkinson’s disease: molecular and thera-
peutic insights from model systems, 1st edn. Academic Press, 
Waltham, pp 237–246
 58. Freundt EC, Maynard N, Clancy EK, Roy S, Bousset L, Sourigues 
Y, Covert M, Melki R, Kirkegaard K, Brahic M (2012) Neuron-
to-neuron transmission of alpha-synuclein fibrils through axonal 
transport. Ann Neurol 72(4):517–524. doi:10.1002/ana.23747
 59. Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah 
E, Goldberg MS, Shen J, Takio K, Iwatsubo T (2002) A-synu-
clein is phosphorylated in synucleinopathy lesions. Nat Cell 
Biol 4:160–164
 60. George JM, Jin H, Woods WS, Clayton DF (1995) Characteri-
zation of a novel protein regulated during the critical period for 
song learning in the zebra finch. Neuron 15(2):361–372
 61. Ghosh D, Mondal M, Mohite GM, Singh PK, Ranjan P, Anoop 
A, Ghosh S, Jha NN, Kumar A, Maji SK (2013) The Parkin-
son’s disease-associated H50Q mutation accelerates alpha-
synuclein aggregation in vitro. Biochemistry 52(40):6925–
6927. doi:10.1021/bi400999d
 62. Ghosh D, Sahay S, Ranjan P, Salot S, Mohite GM, Singh 
PK, Dwivedi S, Carvalho E, Banerjee R, Kumar A, Maji SK 
(2014) The newly discovered Parkinson’s disease associated 
Finnish mutation (A53E) attenuates alpha-synuclein aggrega-
tion and membrane binding. Biochemistry 53(41):6419–6421. 
doi:10.1021/bi5010365
 63. Giasson BI, Duda JE, Forman MS, Lee VM-Y, Trojanoswki JQ 
(2001) Prominent perikaryal expression of α- and β-synuclein 
in neurons of dorsal root ganglion and in medullary neurons. 
Exp Neurol 172:354–362
 64. Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, 
Lee VM (2002) Neuronal alpha-synucleinopathy with severe 
movement disorder in mice expressing A53T human alpha-
synuclein. Neuron 34(4):521–533
 65. Giasson BI, Lee VM-Y (2003) Are ubiquitination pathways 
central to Parkinson’s disease? Cell 114:1–8
 66. Giasson BI, Murray IV, Trojanowski JQ, Lee VM-Y (2001) A 
hydrophobic stretch of 12 amino acid residues in the middle of 
69Acta Neuropathol (2016) 131:49–73 
1 3
alpha-synuclein is essential for filament assembly. J Biol Chem 
276:2380–2386
 67. Giasson BI, Uryu K, Trojanowski JQ, Lee VM-Y (1999) 
Mutant and wild type human alpha-synucleins assemble into 
elongated filaments with distinct morphologies in vitro. J Biol 
Chem 274(12):7619–7622
 68. Goedert M (2001) Alpha-synuclein and neurodegenerative dis-
eases. Nat Rev Neurosci 2:492–501
 69. Goedert M, Spillantini MG, Del Tredici K, Braak H (2013) 
100 years of Lewy pathology. Nat Rev Neurol 9(1):13–24. 
doi:10.1038/nrneurol.2012.242
 70. Golde TE, Borchelt DR, Giasson BI, Lewis J (2013) Thinking 
laterally about neurodegenerative proteinopathies. J Clin Invest 
123:1847–1855
 71. Goldman JE, Yen SH, Chiu FC, Peress NS (1983) Lewy bodies 
of Parkinson’s disease contain neurofilament antigens. Science 
221(4615):1082–1084
 72. Greenbaum EA, Graves CL, Mishizen-Eberz AJ, Lupoli MA, 
Lynch DR, Englander SW, Axelsen PH, Giasson BI (2005) The 
E46K mutation in alpha -synuclein increases amyloid fibril for-
mation. J Biol Chem 280(9):7800–7807
 73. Greenfield JG, Bosanquet FD (1953) The brain-stem lesions in 
parkinsonism. J Neurol Neurosurg Psychiatry 16(4):213–226
 74. Greffard S, Verny M, Bonnet AM, Seilhean D, Hauw JJ, Duyc-
kaerts C (2010) A stable proportion of Lewy body bearing neu-
rons in the substantia nigra suggests a model in which the Lewy 
body causes neuronal death. Neurobiol Aging 31(1):99–103. 
doi:10.1016/j.neurobiolaging.2008.03.015
 75. Guo JL, Covell DJ, Daniels JP, Iba M, Stieber A, Zhang B, Rid-
dle DM, Kwong LK, Xu Y, Trojanowski JQ, Lee VM (2013) 
Distinct alpha-synuclein strains differentially promote tau 
inclusions in neurons. Cell 154(1):103–117. doi:10.1016/j.
cell.2013.05.057
 76. Haelterman NA, Yoon WH, Sandoval H, Jaiswal M, Shul-
man JM, Bellen HJ (2014) A mitocentric view of Parkin-
son’s disease. Annu Rev Neurosci 37:137–159. doi:10.1146/
annurev-neuro-071013-014317
 77. Hague K, Lento P, Morgello S, Caro S, Kaufmann H (1997) 
The distribution of Lewy bodies in pure autonomic failure: 
autopsy findings and review of the literature. Acta Neuropathol 
94(2):192–196
 78. Halliday G, Hely M, Reid W, Morris J (2008) The progression 
of pathology in longitudinally followed patients with Parkin-
son’s disease. Acta Neuropathol 115(4):409–415. doi:10.1007/
s00401-008-0344-8
 79. Hashimoto M, Hsu LJ, Sisk A, Xia Y, Takeda A, Sundsmo M, 
Masliah E (1998) Human recombinant NACP/alpha-synuclein 
is aggregated and fibrillated in vitro: relevance for Lewy body 
disease. Brain Res 799(2):301–306
 80. Hauser DN, Hastings TG (2013) Mitochondrial dysfunc-
tion and oxidative stress in Parkinson’s disease and mono-
genic parkinsonism. Neurobiol Dis 51:35–42. doi:10.1016/j.
nbd.2012.10.011
 81. Hawkes CH, Del Tredici K, Braak H (2007) Parkinson’s dis-
ease: a dual-hit hypothesis. Neuropathol Appl Neurobiol 
33(6):599–614. doi:10.1111/j.1365-2990.2007.00874.x
 82. Henderson JM, Carpenter K, Cartwright H, Halliday GM 
(2000) Degeneration of the centre median-parafascicular com-
plex in Parkinson’s disease. Ann Neurol 47(3):345–352
 83. Hilton D, Stephens M, Kirk L, Edwards P, Potter R, Zajicek 
J, Broughton E, Hagan H, Carroll C (2014) Accumulation 
of alpha-synuclein in the bowel of patients in the pre-clinical 
phase of Parkinson’s disease. Acta Neuropathol 127(2):235–
241. doi:10.1007/s00401-013-1214-6
 84. Höglinger GU, Alvarez-Fischer D, Arias-Carrión O, Djufri M, 
Windolph A, Keber U, Borta A, Ries V, Schwarting RK, Scheller 
D, Oertel WH (2015) A new dopaminergic nigro-olfactory pro-
jection. Acta Neuropathol. doi:10.1007/s00401-015-1451-y
 85. Hornykiewicz O (1998) Biochemical aspects of Parkinson’s 
disease. Neurology 51(2 Suppl 2):S2–S9
 86. Howlett DR, Whitfield D, Johnson M, Attems J, O’Brien JT, 
Aarsland D, Lai MK, Lee JH, Chen C, Ballard C, Hortobagyi T, 
Francis PT (2015) Regional multiple pathology scores are asso-
ciated with cognitive decline in Lewy body dementias. Brain 
Pathol 25(4):401–408. doi:10.1111/bpa.12182
 87. Irizarry MC, Kim TW, McNamara M, Tanzi RE, George JM, 
Clayton DF, Hyman BT (1996) Characterization of the pre-
cursor protein of the non-A beta component of senile plaques 
(NACP) in the human central nervous system. J Neuropathol 
Exp Neurol 55(8):889–895
 88. Iwai A, Masliah E, Yoshimoto M, Ge N, Flanagan L, de Silva 
HA, Kittel A, Saitoh T (1995) The precursor protein of non-A 
beta component of Alzheimer’s disease amyloid is a presynaptic 
protein of the central nervous system. Neuron 14(2):467–475
 89. Jakes R, Spillantini MG, Goedert M (1994) Identification of two 
distinct synucleins from human brain. FEBS Lett 345(1):27–32
 90. Jellinger KA (2012) Neuropathology of sporadic Parkinson’s 
disease: evaluation and changes of concepts. Mov Disord 
27(1):8–30. doi:10.1002/mds.23795
 91. Kalaitzakis ME, Graeber MB, Gentleman SM, Pearce RK 
(2008) Controversies over the staging of alpha-synuclein pathol-
ogy in Parkinson’s disease. Acta Neuropathol 116(1):125–128. 
doi:10.1007/s00401-008-0381-3
 92. Kanazawa T, Adachi E, Orimo S, Nakamura A, Mizusawa H, 
Uchihara T (2012) Pale neurites, premature alpha-synuclein 
aggregates with centripetal extension from axon collaterals. Brain 
Pathol 22(1):67–78. doi:10.1111/j.1750-3639.2011.00509.x
 93. Kanazawa T, Uchihara T, Takahashi A, Nakamura A, Orimo S, 
Mizusawa H (2008) Three-layered structure shared between 
Lewy bodies and Lewy neurites—three-dimensional recon-
struction of triple-labeled sections. Brain Pathol 18(3):415–422. 
doi:10.1111/j.1750-3639.2008.00140.x
 94. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cot-
man CW, Glabe CG (2003) Common structure of soluble amy-
loid oligomers implies common mechanism of pathogenesis. 
Science 300(5618):486–489
 95. Khalaf O, Fauvet B, Oueslati A, Dikiy I, Mahul-Mellier AL, 
Ruggeri FS, Mbefo MK, Vercruysse F, Dietler G, Lee SJ, 
Eliezer D, Lashuel HA (2014) The H50Q mutation enhances 
alpha-synuclein aggregation, secretion, and toxicity. J Biol 
Chem 289(32):21856–21876. doi:10.1074/jbc.M114.553297
 96. Kiely AP, Asi YT, Kara E, Limousin P, Ling H, Lewis P, Prouka-
kis C, Quinn N, Lees AJ, Hardy J, Revesz T, Houlden H, Holton 
JL (2013) Alpha-synucleinopathy associated with G51D SNCA 
mutation: a link between Parkinson’s disease and multiple sys-
tem atrophy? Acta Neuropathol 125(5):753–769. doi:10.1007/
s00401-013-1096-7
 97. Kim C, Ho DH, Suk JE, You S, Michael S, Kang J, Joong LS, 
Masliah E, Hwang D, Lee HJ, Lee SJ (2013) Neuron-released 
oligomeric alpha-synuclein is an endogenous agonist of TLR2 
for paracrine activation of microglia. Nat Commun 4:1562. 
doi:10.1038/ncomms2534
 98. Kim YS, Laurine E, Woods W, Lee SJ (2006) A novel mech-
anism of interaction between alpha-synuclein and biologi-
cal membranes. J Mol Biol 360(2):386–397. doi:10.1016/j.
jmb.2006.05.004
 99. Kirik D, Annett LE, Burger C, Muzyczka N, Mandel RJ, 
Bjorklund A (2003) Nigrostriatal alpha-synucleinopathy 
induced by viral vector-mediated overexpression of human 
alpha-synuclein: a new primate model of Parkinson’s disease. 
Proc Natl Acad Sci USA 100(5):2884–2889. doi:10.1073/
pnas.0536383100
70 Acta Neuropathol (2016) 131:49–73
1 3
 100. Kirik D, Rosenblad C, Burger C, Lundberg C, Johansen TE, 
Muzyczka N, Mandel RJ, Bjorklund A (2002) Parkinson-
like neurodegeneration induced by targeted overexpression 
of alpha-synuclein in the nigrostriatal system. J Neurosci 
22(7):2780–2791
 101. Klein RL, King MA, Hamby ME, Meyer EM (2002) Dopamin-
ergic cell loss induced by human A30P alpha-synuclein gene 
transfer to the rat substantia nigra. Hum Gene Ther 13(5):605–
612. doi:10.1089/10430340252837206
 102. Kosaka K (1978) Lewy bodies in cerebral cortex, report of three 
cases. Acta Neuropathol 42(2):127–134
 103. Kosaka K, Iseki E, Odawara T, Yamamoto T (1996) Cerebral 
type of Lewy body disease. Neuropathology 16:32–35
 104. Kovacs GG, Alafuzoff I, Al-Sarraj S, Arzberger T, Bogdanovic 
N, Capellari S, Ferrer I, Gelpi E, Kovari V, Kretzschmar H, 
Nagy Z, Parchi P, Seilhean D, Soininen H, Troakes C, Budka 
H (2008) Mixed brain pathologies in dementia: the BrainNet 
Europe consortium experience. Dement Geriatr Cogn Disord 
26(4):343–350. doi:10.1159/000161560
 105. Kovacs GG, Wagner U, Dumont B, Pikkarainen M, Osman AA, 
Streichenberger N, Leisser I, Verchere J, Baron T, Alafuzoff I, 
Budka H, Perret-Liaudet A, Lachmann I (2012) An antibody 
with high reactivity for disease-associated alpha-synuclein 
reveals extensive brain pathology. Acta Neuropathol 124(1):37–
50. doi:10.1007/s00401-012-0964-x
 106. Kramer ML, Schulz-Schaeffer WJ (2007) Presynaptic alpha-
synuclein aggregates, not Lewy bodies, cause neurodegen-
eration in dementia with Lewy bodies. J Neurosci 27(6):1405–
1410. doi:10.1523/JNEUROSCI.4564-06.2007
 107. Krüger R, Kuhn W, Müller T, Woitalla D, Graeber M, Kosel 
S, Przuntek H, Epplen JT, Schöls L, Riess O (1998) Ala30Pro 
mutation in the gene encoding alpha-synuclein in Parkinson’s 
disease. Nat Genet 18(2):106–108
 108. Lee HJ, Khoshaghideh F, Patel S, Lee SJ (2004) Clearance 
of alpha-synuclein oligomeric intermediates via the lyso-
somal degradation pathway. J Neurosci 24(8):1888–1896. 
doi:10.1523/JNEUROSCI.3809-03.2004
 109. Lee HJ, Patel S, Lee SJ (2005) Intravesicular localization and 
exocytosis of alpha-synuclein and its aggregates. J Neurosci 
25(25):6016–6024
 110. Lee HJ, Suk JE, Bae EJ, Lee JH, Paik SR, Lee SJ (2008) 
Assembly-dependent endocytosis and clearance of extracellular 
alpha-synuclein. Int J Biochem Cell Biol 40(9):1835–1849
 111. Lee HJ, Suk JE, Bae EJ, Lee SJ (2008) Clearance and depo-
sition of extracellular alpha-synuclein aggregates in microglia. 
Biochem Biophys Res Commun 372(3):423–428. doi:10.1016/j.
bbrc.2008.05.045
 112. Lee HJ, Suk JE, Patrick C, Bae EJ, Cho JH, Rho S, Hwang D, 
Masliah E, Lee SJ (2010) Direct transfer of alpha-synuclein 
from neuron to astroglia causes inflammatory responses in 
synucleinopathies. J Biol Chem 285(12):9262–9272
 113. Lees AJ (2009) The Parkinson chimera. Neurology 72(7 
Suppl):S2–S11. doi:10.1212/WNL.0b013e318198daec
 114. Lees AJ, Selikhova M, Andrade LA, Duyckaerts C (2008) The 
black stuff and Konstantin Nikolaevich Tretiakoff. Mov Disord 
23(6):777–783. doi:10.1002/mds.21855
 115. Lema Tomé CM, Tyson T, Rey NL, Grathwohl S, Britschgi M, 
Brundin P (2013) Inflammation and alpha-synuclein’s prion-
like behavior in Parkinson’s disease—is there a link? Mol Neu-
robiol 47(2):561–574. doi:10.1007/s12035-012-8267-8
 116. Lesage S, Anheim M, Letournel F, Bousset L, Honore A, Rozas 
N, Pieri L, Madiona K, Dürr A, Melki R, Verny C, Brice A 
(2013) G51D alpha-synuclein mutation causes a novel Par-
kinsonian-pyramidal syndrome. Ann Neurol 73(4):459–471. 
doi:10.1002/ana.23894
 117. Lesuisse C, Xu G, Anderson J, Wong M, Jankowsky J, Holtz G, 
Gonzalez V, Wong PC, Price DL, Tang F, Wagner S, Borchelt 
DR (2001) Hyper-expression of human apolipoprotein E4 in 
astroglia and neurons does not enhance amyloid deposition in 
transgenic mice. Hum Mol Genet 10(22):2525–2537
 118. Li J, Uversky VN, Fink AL (2001) Effect of familial Parkin-
son’s disease point mutations A30P and A53T on the structural 
properties, aggregation, and fibrillation of human alpha-synu-
clein. Biochemistry 40(38):11604–11613
 119. Lingor P, Koch JC, Tonges L, Bahr M (2012) Axonal degen-
eration as a therapeutic target in the CNS. Cell Tissue Res 
349(1):289–311. doi:10.1007/s00441-012-1362-3
 120. Liu CW, Giasson BI, Lewis KA, Lee VM, Demartino GN, 
Thomas PJ (2005) A precipitating role for truncated alpha-
synuclein and the proteasome in alpha-synuclein aggregation: 
implications for pathogenesis of Parkinson disease. J Biol 
Chem 280(24):22670–22678. doi:10.1074/jbc.M501508200
 121. Liu J, Zhang JP, Shi M, Quinn T, Bradner J, Beyer R, Chen S, 
Zhang J (2009) Rab11a and hsp90 regulate recycling of extra-
cellular alpha-synuclein. J Neurosci 29(5):1480–1485
 122. Lo Bianco C, Ridet JL, Schneider BL, Deglon N, Aebischer P 
(2002) Alpha-synucleinopathy and selective dopaminergic neu-
ron loss in a rat lentiviral-based model of Parkinson’s disease. 
Proc Natl Acad Sci USA 99(16):10813–10818. doi:10.1073/
pnas.152339799
 123. Louis ED, Honig LS, Vonsattel JP, Maraganore DM, Borden S, 
Moskowitz CB (2005) Essential tremor associated with focal 
nonnigral Lewy bodies: a clinicopathologic study. Arch Neurol 
62(6):1004–1007. doi:10.1001/archneur.62.6.1004
 124. Luk KC, Kehm V, Carroll J, Zhang B, O’Brien P, Trojanow-
ski JQ, Lee VM (2012) Pathological alpha-synuclein trans-
mission initiates Parkinson-like neurodegeneration in non-
transgenic mice. Science 338(6109):949–953. doi:10.1126/
science.1227157
 125. Luk KC, Kehm VM, Zhang B, O’Brien P, Trojanowski JQ, Lee 
VM (2012) Intracerebral inoculation of pathological alpha-
synuclein initiates a rapidly progressive neurodegenerative 
alpha-synucleinopathy in mice. J Exp Med 209(5):975–986. 
doi:10.1084/jem.20112457
 126. Luk KC, Song C, O’Brien P, Stieber A, Branch JR, Brunden 
KR, Trojanowski JQ, Lee VM (2009) Exogenous alpha-synu-
clein fibrils seed the formation of Lewy body-like intracel-
lular inclusions in cultured cells. Proc Natl Acad Sci USA 
106(47):20051–20056
 127. Manzoni C, Lewis PA (2013) Dysfunction of the autophagy/lys-
osomal degradation pathway is a shared feature of the genetic 
synucleinopathies. FASEB J 27(9):3424–3429. doi:10.1096/
fj.12-223842
 128. Martin I, Dawson VL, Dawson TM (2011) Recent 
advances in the genetics of Parkinson’s disease. Annu 
Rev Genomics Hum Genet 12:301–325. doi:10.1146/
annurev-genom-082410-101440
 129. Masuda-Suzukake M, Nonaka T, Hosokawa M, Kubo M, Shi-
mozawa A, Akiyama H, Hasegawa M (2014) Pathological 
alpha-synuclein propagates through neural networks. Acta Neu-
ropathol Commun 2:88. doi:10.1186/s40478-014-0088-8
 130. Masuda-Suzukake M, Nonaka T, Hosokawa M, Oikawa T, 
Arai T, Akiyama H, Mann DM, Hasegawa M (2013) Prion-
like spreading of pathological alpha-synuclein in brain. Brain 
136(Pt 4):1128–1138. doi:10.1093/brain/awt037
 131. Matsuda W, Furuta T, Nakamura KC, Hioki H, Fujiyama F, 
Arai R, Kaneko T (2009) Single nigrostriatal dopaminergic neu-
rons form widely spread and highly dense axonal arborizations 
in the neostriatum. J Neurosci 29(2):444–453. doi:10.1523/
JNEUROSCI.4029-08.2009
71Acta Neuropathol (2016) 131:49–73 
1 3
 132. McCann H, Stevens CH, Cartwright H, Halliday GM (2014) Α-synucleinopathy phenotypes. Parkinsonism Relat Disord 
20:S62–S67. doi:10.1016/s1353-8020(13)70017-8
 133. Miki Y, Mori F, Wakabayashi K, Kuroda N, Orimo S (2009) 
Incidental Lewy body disease restricted to the heart and stel-
late ganglia. Mov Disord 24(15):2299–2301. doi:10.1002/
mds.22775
 134. Miller DW, Johnson JM, Solano SM, Hollingsworth ZR, Stan-
daert DG, Young AB (2005) Absence of alpha-synuclein mRNA 
expression in normal and multiple system atrophy oligoden-
droglia. J Neural Transm 112(12):1613–1624. doi:10.1007/
s00702-005-0378-1
 135. Minguez-Castellanos A, Chamorro CE, Escamilla-Sevilla 
F, Ortega-Moreno A, Rebollo AC, Gomez-Rio M, Con-
cha A, Munoz DG (2007) Do alpha-synuclein aggregates 
in autonomic plexuses predate Lewy body disorders?: a 
cohort study. Neurology 68(23):2012–2018. doi:10.1212/01.
wnl.0000264429.59379.d9
 136. Mizuno Y, Hattori N, Mochizuki H (2007) Genetic aspects 
of Parkinson’s disease. Handb Clin Neurol 83:217–244. 
doi:10.1016/s0072-9752(07)83009-0
 137. Mougenot AL, Nicot S, Bencsik A, Morignat E, Verchere 
J, Lakhdar L, Legastelois S, Baron T (2012) Prion-like 
acceleration of a synucleinopathy in a transgenic mouse 
model. Neurobiol Aging 33(9):2225–2228. doi:10.1016/j.
neurobiolaging.2011.06.022
 138. Narhi L, Wood SJ, Steavenson S, Jiang Y, Wu GM, Anafi D, 
Kaufman SA, Martin F, Sitney K, Denis P, Louis JC, Wypych 
J, Biere AL, Citron M (1999) Both familial Parkinson’s disease 
mutations accelerate alpha-synuclein aggregation. J Biol Chem 
274(14):9843–9846
 139. Nolte J, Angevine JB (2007) The human brain in photographs 
and diagrams, 3rd edn. Mosby/Elsevier, Philadelphia
 140. Nonaka T, Watanabe ST, Iwatsubo T, Hasegawa M (2010) 
Seeded aggregation and toxicity of alpha-synuclein and tau: 
cellular models of neurodegenerative diseases. J Biol Chem 
285(45):34885–34898. doi:10.1074/jbc.M110.148460
 141. Okazaki H, Lipkin LE, Aronson SM (1961) Diffuse intracyto-
plasmic ganglionic inclusions (Lewy type) associated with pro-
gressive dementia and quadriparesis in flexion. J Neuropathol 
Exp Neurol 20:237–244
 142. Orimo S, Suzuki M, Inaba A, Mizusawa H (2012) 123I-MIBG 
myocardial scintigraphy for differentiating Parkinson’s dis-
ease from other neurodegenerative Parkinsonism: a system-
atic review and meta-analysis. Parkinsonism Relat Disord 
18(5):494–500. doi:10.1016/j.parkreldis.2012.01.009
 143. Orimo S, Uchihara T, Nakamura A, Mori F, Kakita A, Waka-
bayashi K, Takahashi H (2008) Axonal alpha-synuclein 
aggregates herald centripetal degeneration of cardiac sympa-
thetic nerve in Parkinson’s disease. Brain 131(Pt 3):642–650. 
doi:10.1093/brain/awm302
 144. Parkkinen L, Pirttila T, Alafuzoff I (2008) Applicability of cur-
rent staging/categorization of alpha-synuclein pathology and 
their clinical relevance. Acta Neuropathol 115(4):399–407. 
doi:10.1007/s00401-008-0346-6
 145. Pasanen P, Myllykangas L, Siitonen M, Raunio A, Kaak-
kola S, Lyytinen J, Tienari PJ, Poyhonen M, Paetau A (2014) 
Novel alpha-synuclein mutation A53E associated with atypi-
cal multiple system atrophy and Parkinson’s disease-type 
pathology. Neurobiol Aging 35(9):2180–2185. doi:10.1016/j.
neurobiolaging.2014.03.024
 146. Paumier KL, Luk KC, Manfredsson FP, Kanaan NM, Lipton 
JW, Collier TJ, Steece-Collier K, Kemp CJ, Celano S, Schulz 
E, Sandoval IM, Fleming S, Dirr E, Polinski NK, Trojanow-
ski JQ, Lee VM, Sortwell CE (2015) Intrastriatal injection of 
pre-formed mouse alpha-synuclein fibrils into rats triggers 
alpha-synuclein pathology and bilateral nigrostriatal degenera-
tion. Neurobiol Dis 82:185–199. doi:10.1016/j.nbd.2015.06.003
 147. Peelaerts W, Bousset L, Van der Perren A, Moskalyuk A, Pulizzi 
R, Giugliano M, Van den Haute C, Melki R, Baekelandt V 
(2015) Alpha-synuclein strains cause distinct synucleinopathies 
after local and systemic administration. Nature 522(7556):340–
344. doi:10.1038/nature14547
 148. Pikkarainen M, Martikainen P, Alafuzoff I (2010) The effect 
of prolonged fixation time on immunohistochemical staining 
of common neurodegenerative disease markers. J Neuropathol 
Exp Neurol 69(1):40–52. doi:10.1097/NEN.0b013e3181c6c13d
 149. Pissadaki EK, Bolam JP (2013) The energy cost of action 
potential propagation in dopamine neurons: clues to suscep-
tibility in Parkinson’s disease. Front Comput Neurosci 7:13. 
doi:10.3389/fncom.2013.00013
 150. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, 
Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, 
Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, 
Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe 
LI, Nussbaum RL (1997) Mutation in the alpha-synuclein 
gene identified in families with Parkinson’s disease. Science 
276(5321):2045–2047
 151. Proukakis C, Dudzik CG, Brier T, Mackay DS, Cooper JM, 
Millhauser GL, Houlden H, Schapira AH (2013) A novel alpha-
synuclein missense mutation in Parkinson disease. Neurology 
80(11):1062–1064. doi:10.1212/WNL.0b013e31828727ba
 152. Recasens A, Dehay B, Bove J, Carballo-Carbajal I, Dovero 
S, Perez-Villalba A, Fernagut PO, Blesa J, Parent A, Perier 
C, Farinas I, Obeso JA, Bezard E, Vila M (2014) Lewy body 
extracts from Parkinson disease brains trigger alpha-synuclein 
pathology and neurodegeneration in mice and monkeys. Ann 
Neurol 75(3):351–362. doi:10.1002/ana.24066
 153. Rey NL, Petit GH, Bousset L, Melki R, Brundin P (2013) 
Transfer of human alpha-synuclein from the olfactory bulb 
to interconnected brain regions in mice. Acta Neuropathol 
126(4):555–573. doi:10.1007/s00401-013-1160-3
 154. Reyes JF, Rey NL, Bousset L, Melki R, Brundin P, Angot E 
(2013) Alpha-synuclein transfers from neurons to oligodendro-
cytes. Glia 62(3):387–398. doi:10.1002/glia.22611
 155. Roberts RF, Wade-Martins R, Alegre-Abarrategui J (2015) 
Direct visualization of alpha-synuclein oligomers reveals previ-
ously undetected pathology in Parkinson’s disease brain. Brain 
138(Pt 6):1642–1657. doi:10.1093/brain/awv040
 156. Roodveldt C, Christodoulou J, Dobson CM (2008) Immuno-
logical features of alpha-synuclein in Parkinson’s disease. J Cell 
Mol Med 12(5B):1820–1829
 157. Rutherford NJ, Giasson BI (2015) The A53E alpha-synuclein 
pathological mutation demonstrates reduced aggregation pro-
pensity in vitro and in cell culture. Neurosci Lett 597:43–48. 
doi:10.1016/j.neulet.2015.04.022
 158. Rutherford NJ, Moore BD, Golde TE, Giasson BI (2014) Diver-
gent effects of the H50Q and G51D SNCA mutations on the 
aggregation of alpha-synuclein. J Neurochem 131(6):859–867. 
doi:10.1111/jnc.12806
 159. Sacino AN, Brooks M, McGarvey NH, McKinney AB, Thomas 
MA, Levites Y, Ran Y, Golde TE, Giasson BI (2013) Induction 
of CNS alpha-synuclein pathology by fibrillar and non-amyloi-
dogenic recombinant alpha-synuclein. Acta Neuropathol Com-
mun 1(1):38. doi:10.1186/2051-5960-1-38
 160. Sacino AN, Brooks M, McKinney AB, Thomas MA, Shaw G, 
Golde TE, Giasson BI (2014) Brain injection of alpha-synu-
clein induces multiple proteinopathies, gliosis, and a neuronal 
injury marker. J Neurosci 34(37):12368–12378. doi:10.1523/
JNEUROSCI.2102-14.2014
 161. Sacino AN, Brooks M, Thomas MA, McKinney AB, Lee 
S, Regenhardt RW, McGarvey NH, Ayers JI, Notterpek L, 
72 Acta Neuropathol (2016) 131:49–73
1 3
Borchelt DR, Golde TE, Giasson BI (2014) Intramuscular injec-
tion of alpha-synuclein induces CNS alpha-synuclein pathol-
ogy and a rapid-onset motor phenotype in transgenic mice. 
Proc Natl Acad Sci USA 111(29):10732–10737. doi:10.1073/
pnas.1321785111
 162. Sacino AN, Brooks M, Thomas MA, McKinney AB, McGarvey 
NH, Rutherford NJ, Ceballos-Diaz C, Robertson J, Golde TE, 
Giasson BI (2014) Amyloidogenic alpha-synuclein seeds do not 
invariably induce rapid, widespread pathology in mice. Acta 
Neuropathol 127(7):645–665. doi:10.1007/s00401-014-1268-0
 163. Sacino AN, Thomas MA, Ceballos-Diaz C, Cruz PE, Rosario 
AM, Lewis J, Giasson BI, Golde TE (2013) Conformational 
templating of alpha-synuclein aggregates in neuronal-glial cul-
tures. Mol Neurodegener 8:17. doi:10.1186/1750-1326-8-17
 164. Sano I, Taniguchi K, Gamo T, Takesada M, Kakimoto Y 
(1960) Die Katechinamine im Zentralnervensystem. Klinische 
Wochenschrift 38:57–62
 165. Schweighauser M, Bacioglu M, Fritschi SK, Shimshek DR, 
Kahle PJ, Eisele YS, Jucker M (2015) Formaldehyde-fixed brain 
tissue from spontaneously ill alpha-synuclein transgenic mice 
induces fatal alpha-synucleinopathy in transgenic hosts. Acta 
Neuropathol 129(1):157–159. doi:10.1007/s00401-014-1360-5
 166. Serpell LC, Berriman J, Jakes R, Goedert M, Crowther RA 
(2000) Fiber diffraction of synthetic alpha-synuclein filaments 
shows amyloid-like cross-beta conformation. Proc Natl Acad 
Sci USA 97(9):4897–4902
 167. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, 
Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum 
R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, 
Cookson MR, Muenter M, Baptista M, Miller D, Blancato J, 
Hardy J, Gwinn-Hardy K (2003) Alpha-synuclein locus triplica-
tion causes Parkinson’s disease. Science 302(5646):841
 168. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes 
R, Goedert M (1997) Alpha-synuclein in Lewy bodies. Nature 
388(6645):839–840. doi:10.1038/42166
 169. Subramaniam SR, Chesselet MF (2013) Mitochondrial dys-
function and oxidative stress in parkinson’s disease. Prog Neu-
robiol 106–107:17–32. doi:10.1016/j.pneurobio.2013.04.004
 170. Sulzer D, Surmeier DJ (2013) Neuronal vulnerability, patho-
genesis, and Parkinson’s disease. Mov Disord 28(1):41–50. 
doi:10.1002/mds.25095
 171. Sung JY, Kim J, Paik SR, Park JH, Ahn YS, Chung KC (2001) 
Induction of neuronal cell death by Rab5a-dependent endocy-
tosis of alpha-synuclein. J Biol Chem 276(29):27441–27448. 
doi:10.1074/jbc.M101318200
 172. Takahashi M, Ikemura M, Oka T, Uchihara T, Wakabayashi K, 
Kakita A, Takahashi H, Yoshida M, Toru S, Kobayashi T, Orimo 
S (2015) Quantitative correlation between cardiac MIBG uptake 
and remaining axons in the cardiac sympathetic nerve in Lewy 
body disease. J Neurol Neurosurg Psychiatry 86(9):939–944. 
doi:10.1136/jnnp-2015-310686
 173. Tran HT, Chung CH, Iba M, Zhang B, Trojanowski JQ, 
Luk KC, Lee VM (2014) Alpha-synuclein immunotherapy 
blocks uptake and templated propagation of misfolded alpha-
synuclein and neurodegeneration. Cell Rep 7(6):2054–2065. 
doi:10.1016/j.celrep.2014.05.033
 174. Ubeda-Banon I, Saiz-Sanchez D, de la Rosa-Prieto C, Mar-
tinez-Marcos A (2014) Alpha-synuclein in the olfactory system 
in Parkinson’s disease: role of neural connections on spreading 
pathology. Brain Struct Funct 219(5):1513–1526. doi:10.1007/
s00429-013-0651-2
 175. Uchihara T (2007) Silver diagnosis in neuropathology: prin-
ciples, practice and revised interpretation. Acta Neuropathol 
113(5):483–499. doi:10.1007/s00401-007-0200-2
 176. Ulusoy A, Rusconi R, Perez-Revuelta BI, Musgrove RE, 
Helwig M, Winzen-Reichert B, Di Monte DA (2013) 
Caudo-rostral brain spreading of alpha-synuclein through vagal 
connections. EMBO Mol Med 5(7):1051–1059. doi:10.1002/
emmm.201302475
 177. Uversky VN, Li J, Fink AL (2001) Evidence for a partially-
folded intermediate in alpha-synuclein fibril formation. J Biol 
Chem 276(14):10737–10744
 178. Vekrellis K, Xilouri M, Emmanouilidou E, Rideout HJ, Stefanis 
L (2011) Pathological roles of alpha-synuclein in neurologi-
cal disorders. Lancet Neurol 10(11):1015–1025. doi:10.1016/
S1474-4422(11)70213-7
 179. Volpicelli-Daley LA, Luk KC, Patel TP, Tanik SA, Riddle DM, 
Stieber A, Meaney DF, Trojanowski JQ, Lee VM (2011) Exog-
enous alpha-synuclein fibrils induce Lewy body pathology lead-
ing to synaptic dysfunction and neuron death. Neuron 72(1):57–
71. doi:10.1016/j.neuron.2011.08.033
 180. Wakabayashi K, Mori F, Tanji K, Orimo S, Takahashi H (2010) 
Involvement of the peripheral nervous system in synucleinopa-
thies, tauopathies and other neurodegenerative proteinopathies 
of the brain. Acta Neuropathol 120(1):1–12. doi:10.1007/
s00401-010-0706-x
 181. Wang J, Xu G, Slunt HH, Gonzales V, Coonfield M, Fromholt 
D, Copeland NG, Jenkins NA, Borchelt DR (2005) Coincident 
thresholds of mutant protein for paralytic disease and protein 
aggregation caused by restrictively expressed superoxide dis-
mutase cDNA. Neurobiol Dis 20(3):943–952. doi:10.1016/j.
nbd.2005.06.005
 182. Wang ZY, Lian H, Cai QQ, Song HY, Zhang XL, Zhou L, Zhang 
YM, Zheng LF, Zhu JX (2014) No direct projection is observed 
from the substantia nigra to the dorsal vagus complex in the rat. 
J Parkinsons Dis 4(3):375–383. doi:10.3233/JPD-130279
 183. Warren JD, Rohrer JD, Schott JM, Fox NC, Hardy J, Ros-
sor MN (2013) Molecular nexopathies: a new paradigm of 
neurodegenerative disease. Trends Neurosci 36(10):561–569. 
doi:10.1016/j.tins.2013.06.007
 184. Watts JC, Giles K, Oehler A, Middleton L, Dexter DT, Gentleman 
SM, DeArmond SJ, Prusiner SB (2013) Transmission of multiple 
system atrophy prions to transgenic mice. Proc Natl Acad Sci 
USA 110(48):19555–19560. doi:10.1073/pnas.1318268110
 185. Waxman EA, Duda JE, Giasson BI (2008) Characterization of 
antibodies that selectively detect alpha-synuclein in pathologi-
cal inclusions. Acta Neuropathol 116(1):37–46
 186. Waxman EA, Giasson BI (2008) Molecular mechanisms of 
alpha-synuclein neurodegeneration. Biochim Biophys Acta 
1792:616–624
 187. Waxman EA, Giasson BI (2008) Specificity and regulation of 
casein kinase-mediated phosphorylation of alpha-synuclein. J 
Neuropathol Exp Neurol 67(5):402–416
 188. Waxman EA, Giasson BI (2010) A novel, high-efficiency cellu-
lar model of fibrillar alpha-synuclein inclusions and the exami-
nation of mutations that inhibit amyloid formation. J Neuro-
chem 113(2):374–388
 189. Waxman EA, Mazzulli JR, Giasson BI (2009) Characteriza-
tion of hydrophobic residue requirements for alpha-synuclein 
fibrillization. Biochemistry 48(40):9427–9436. doi:10.1021/
bi900539p
 190. Westlund KN, Coulter JD (1980) Descending projections of the 
locus coeruleus and subcoeruleus/medial parabrachial nuclei in 
monkey: axonal transport studies and dopamine-beta-hydroxy-
lase immunocytochemistry. Brain Res 2(3):235–264
 191. Wood SJ, Wypych J, Steavenson S, Louis JC, Citron M, Biere 
AL (1999) Alpha-synuclein fibrillogenesis is nucleation-
dependent. Implications for the pathogenesis of Parkinson’s dis-
ease. J Biol Chem 274(28):19509–19512
 192. Xilouri M, Brekk OR, Stefanis L (2013) Alpha-synuclein and 
protein degradation systems: a reciprocal relationship. Mol 
Neurobiol 47(2):537–551. doi:10.1007/s12035-012-8341-2
73Acta Neuropathol (2016) 131:49–73 
1 3
 193. Yokota O, Tsuchiya K, Uchihara T, Ujike H, Terada S, Taka-
hashi M, Kimura Y, Ishizu H, Akiyama H, Kuroda S (2007) 
Lewy body variant of Alzheimer’s disease or cerebral type 
Lewy body disease? Two autopsy cases of presenile onset 
with minimal involvement of the brainstem. Neuropathology 
27(1):21–35
 194. Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, 
Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atares B, Llor-
ens V, Gomez TE, del Ser T, Munoz DG, de Yebenes JG (2004) 
The new mutation, E46K, of alpha-synuclein causes Parkinson 
and Lewy body dementia. Ann Neurol 55(2):164–173
 195. Zhang W, Wang T, Pei Z, Miller DS, Wu X, Block ML, Wil-
son B, Zhang W, Zhou Y, Hong JS, Zhang J (2005) Aggregated 
alpha-synuclein activates microglia: a process leading to disease 
progression in Parkinson’s disease. FASEB J 19(6):533–542
 196. Zhu M, Fink AL (2003) Lipid binding inhibits alpha-synu-
clein fibril formation. J Biol Chem 278(19):16873–16877. 
doi:10.1074/jbc.M210136200
